AstraZeneca's Baxfendy receives positive EU recommendation for hypertension treatment, marking a significant advancement in pharmaceutical innovation.
| Name | ASTRAZENECA PLC |
|---|---|
| CIK | 0000901832 |
| Tickers | AZN |
| Exchanges | NYSE |
| Entity type | other |
| Category | Large accelerated filer |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 000000000 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | X0 United Kingdom |
| Phone | 011 44 20 7304 5000 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 1 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
AstraZeneca's Baxfendy receives positive EU recommendation for hypertension treatment, marking a significant advancement in pharmaceutical innovation.
AstraZeneca's Imfinzi, combined with enfortumab vedotin, gains FDA approval for muscle-invasive bladder cancer, enhancing treatment options for patients.
AstraZeneca's Klygefa gains FDA approval for treating generalized myasthenia gravis, marking a significant advancement in rare disease therapies.
AstraZeneca's Klygefa (gefurulimab) gains EU approval for treating generalized myasthenia gravis, enhancing treatment options for patients.
AstraZeneca PLC has admitted 11,948 further ordinary shares to trading, reflecting its commitment to employee share schemes and growth in the pharmaceutical sector.
AstraZeneca PLC announces total voting rights of 1,551,065,237 shares, providing key information for shareholders and reflecting industry transparency.
AstraZeneca PLC reports a 7% revenue increase and a 14% rise in core EPS for Q3 2026, reaffirming its guidance for the fiscal year.
AstraZeneca’s Enhertu receives EU approval for treating HER2-positive early breast cancer, marking a significant advancement in pharmaceutical therapies.
AstraZeneca's Ultomiris receives FDA approval for IgAN, marking a significant advancement in kidney disease treatment and impacting the pharmaceutical industry.
AstraZeneca has completed its equity investment in Summit, enhancing its portfolio in the pharmaceutical industry.
2062 filing rows loaded from submissions recent; extra archives: CIK0000901832-submissions-001.json (1061 filings, 1995-03-13 to 2019-06-29).
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | 6-K | BAXFENDY RECOMMENDED FOR APPROVAL IN THE EU | 0001654954-26-009815 | 001-11960 | 261555392 | 34 | 68317 | |||
| 2026-11-16 | 6-K | IMFINZI + EV APPROVED IN US IN BLADDER CANCER | 0001654954-26-009811 | 001-11960 | 261555377 | 34 | 52154 | |||
| 2026-11-16 | 6-K | KLYGEFA (GEFURULIMAB) APPROVED IN THE US | 0001654954-26-009808 | 001-11960 | 261555350 | 34 | 43570 | |||
| 2026-11-16 | 6-K | KLYGEFA (GEFURULIMAB) APPROVED IN THE EU | 0001654954-26-009804 | 001-11960 | 261555281 | 34 | 43256 | |||
| 2026-11-10 | 4 | PRIMARY DOCUMENT | 0002122411-26-000003 | 5466 | ||||||
| 2026-11-02 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | 0001654954-26-009359 | 001-11960 | 261510450 | 34 | 34957 | |||
| 2026-11-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-009357 | 001-11960 | 261510412 | 34 | 17461 | |||
| 2026-10-30 | 6-K | 3RD QUARTER RESULTS | 0001654954-26-009256 | 001-11960 | 261504437 | 34 | 1666398 | |||
| 2026-10-27 | 6-K | ENHERTU APPROVED IN EU FOR HER2-POSITIVE EBC | 0001654954-26-009155 | 001-11960 | 261487292 | 34 | 70673 | |||
| 2026-10-22 | 6-K | ULTOMIRIS APPROVED IN US IN IGAN | 0001654954-26-009093 | 001-11960 | 261477204 | 34 | 52408 | |||
| 2026-10-08 | 4 | PRIMARY DOCUMENT | 0002122411-26-000002 | 5464 | ||||||
| 2026-10-05 | 6-K | ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT | 0001654954-26-008783 | 001-11960 | 261438787 | 34 | 22101 | |||
| 2026-10-02 | 6-K | AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY | 0001654954-26-008760 | 001-11960 | 261433401 | 34 | 35848 | |||
| 2026-10-01 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | 0001654954-26-008741 | 001-11960 | 261429771 | 34 | 36928 | |||
| 2026-10-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-008739 | 001-11960 | 261429719 | 34 | 20278 | |||
| 2026-09-29 | 6-K | ASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT | 0001654954-26-008615 | 001-11960 | 261419064 | 34 | 32627 | |||
| 2026-09-23 | 6-K | TRIXEO APPROVED IN EU FOR ASTHMA | 0001654954-26-008520 | 001-11960 | 261398127 | 34 | 42423 | |||
| 2026-09-21 | 6-K | KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP | 0001654954-26-008478 | 001-11960 | 261392263 | 34 | 42167 | |||
| 2026-09-21 | 6-K | ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC | 0001654954-26-008476 | 001-11960 | 261392251 | 34 | 61321 | |||
| 2026-09-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008438 | 001-11960 | 261388678 | 34 | 49393 | |||
| 2026-09-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008369 | 001-11960 | 261379508 | 34 | 46286 | |||
| 2026-09-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008367 | 001-11960 | 261379388 | 34 | 46794 | |||
| 2026-09-14 | 6-K | UPDATE ON SERENA-4 PHASE III TRIAL | 0001654954-26-008323 | 001-11960 | 261375818 | 34 | 44851 | |||
| 2026-09-11 | 4 | OWNERSHIP DOCUMENT | 0001104659-26-107055 | 7668 | ||||||
| 2026-09-08 | 6-K | IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG | 0001654954-26-008172 | 001-11960 | 261363563 | 34 | 51636 | |||
| 2026-09-08 | 6-K | ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER | 0001654954-26-008150 | 001-11960 | 261363305 | 34 | 51318 | |||
| 2026-09-01 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | 0001654954-26-008042 | 001-11960 | 261349449 | 34 | 40189 | |||
| 2026-09-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-008040 | 001-11960 | 261349366 | 34 | 18774 | |||
| 2026-09-01 | 6-K | ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING | 0001654954-26-007992 | 001-11960 | 261348531 | 34 | 35310 | |||
| 2026-09-01 | 6-K | ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC | 0001654954-26-007990 | 001-11960 | 261348523 | 34 | 64359 | |||
| 2026-09-01 | 6-K | DIRECTORATE CHANGE | 0001654954-26-007988 | 001-11960 | 261348512 | 34 | 24339 | |||
| 2026-09-01 | 6-K | ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY | 0001654954-26-007986 | 001-11960 | 261348506 | 34 | 38691 | |||
| 2026-09-01 | 6-K | TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG | 0001654954-26-007983 | 001-11960 | 261348500 | 34 | 57189 | |||
| 2026-08-27 | 6-K | TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS | 0001654954-26-007894 | 001-11960 | 261324999 | 34 | 59555 | |||
| 2026-08-25 | 6-K | ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING | 0001654954-26-007840 | 001-11960 | 261312359 | 34 | 23917 | |||
| 2026-08-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-007742 | 001-11960 | 261293081 | 34 | 47741 | |||
| 2026-08-17 | 6-K | ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER | 0001654954-26-007681 | 001-11960 | 261284757 | 34 | 65794 | |||
| 2026-08-17 | 6-K | UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL | 0001654954-26-007679 | 001-11960 | 261284753 | 34 | 33825 | |||
| 2026-08-17 | 6-K | TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG | 0001654954-26-007677 | 001-11960 | 261284746 | 34 | 60385 | |||
| 2026-08-07 | 4 | PRIMARY DOCUMENT | 0002122411-26-000001 | 5391 | ||||||
| 2026-08-03 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | 0001654954-26-007169 | 001-11960 | 261230993 | 34 | 34901 | |||
| 2026-08-03 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-007166 | 001-11960 | 261230959 | 34 | 19318 | |||
| 2026-07-31 | 6-K | DATROWAY APPROVED IN EU FOR TNBC | 0001654954-26-007050 | 001-11960 | 261225364 | 34 | 60233 | |||
| 2026-07-27 | 6-K | FORM 6-K | 0001104659-26-086846 | 001-11960 | 261202850 | 34 | 13685519 | 1 | 1 | |
| 2026-07-27 | 6-K | UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA | 0001654954-26-006897 | 001-11960 | 261202802 | 34 | 58626 | |||
| 2026-07-27 | 6-K | SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS | 0001654954-26-006895 | 001-11960 | 261202785 | 34 | 53086 | |||
| 2026-07-23 | 6-K | ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER | 0001654954-26-006803 | 001-11960 | 261195084 | 34 | 53779 | |||
| 2026-07-14 | 6-K | ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR | 0001654954-26-006637 | 001-11960 | 261172504 | 34 | 41905 | |||
| 2026-07-09 | 6-K | UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL | 0001654954-26-006554 | 001-11960 | 261163934 | 34 | 40708 | |||
| 2026-07-08 | 4 | OWNERSHIP DOCUMENT | 0001104659-26-081807 | 5618 | ||||||
| 2026-07-01 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | 0001654954-26-006430 | 001-11960 | 261143126 | 34 | 38870 | |||
| 2026-07-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-006427 | 001-11960 | 261143106 | 34 | 17922 | |||
| 2026-06-29 | 11-K | FORM 11-K | 0001683168-26-005159 | 001-11960 | 261134856 | 34 | 2734731 | 1 | 1 | |
| 2026-06-29 | 6-K | ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS | 0001654954-26-006251 | 001-11960 | 261131229 | 34 | 64333 | |||
| 2026-06-29 | 6-K | DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC | 0001654954-26-006239 | 001-11960 | 261131150 | 34 | 56729 | |||
| 2026-06-16 | 4 | OWNERSHIP DOCUMENT | 0001104659-26-074570 | 5617 | ||||||
| 2026-06-15 | 6-K | TRUQAP APPROVED IN US FOR PROSTATE CANCER | 0001654954-26-005964 | 001-11960 | 261089002 | 34 | 47396 | |||
| 2026-06-01 | 6-K | ADMISSION OF FURTHER SECURITIES TO TRADING | 0001654954-26-005587 | 001-11960 | 261047839 | 34 | 40730 | |||
| 2026-06-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-005586 | 001-11960 | 261047833 | 34 | 19612 | |||
| 2026-05-29 | 6-K | IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER | 0001654954-26-005498 | 001-11960 | 261038964 | 34 | 52644 | |||
| 2026-05-28 | 25-NSE | xslF25X02/primary_doc.xml | 0000876661-26-000484 | 001-11960 | 261033256 | 34 | 3791 | |||
| 2026-05-27 | 6-K | US FDA DECISION DATE ON CAMIZESTRANT EXTENDED | 0001654954-26-005381 | 001-11960 | 261022057 | 34 | 47075 | |||
| 2026-05-26 | 6-K | DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC | 0001654954-26-005309 | 001-11960 | 261015925 | 34 | 61824 | |||
| 2026-05-26 | 6-K | ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS | 0001654954-26-005306 | 001-11960 | 261015913 | 34 | 68157 | |||
| 2026-05-26 | 6-K | CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU | 0001654954-26-005303 | 001-11960 | 261015898 | 34 | 50900 | |||
| 2026-05-22 | 4 | OWNERSHIP DOCUMENT | 0001104659-26-065693 | 5568 | ||||||
| 2026-05-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-005049 | 001-11960 | 26991217 | 34 | 46218 | |||
| 2026-05-18 | 6-K | BAXFENDY APPROVED IN THE US FOR HYPERTENSION | 0001654954-26-005044 | 001-11960 | 26991128 | 34 | 56128 | |||
| 2026-05-18 | 6-K | ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS | 0001654954-26-005038 | 001-11960 | 26991097 | 34 | 79471 | |||
| 2026-05-14 | 6-K | IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER | 0001654954-26-004836 | 001-11960 | 26975832 | 34 | 52629 | |||
| 2026-05-08 | 4 | OWNERSHIP DOCUMENT | 0001104659-26-057906 | 7498 | ||||||
| 2026-05-01 | 6-K | TOTAL VOTING RIGHTS AND ADMISSION OF SHARES | 0001654954-26-004247 | 001-11960 | 26929722 | 34 | 43223 | |||
| 2026-05-01 | 6-K | FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER | 0001654954-26-004229 | 001-11960 | 26929154 | 34 | 53217 | |||
| 2026-05-01 | 6-K | FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER | 0001654954-26-004226 | 001-11960 | 26929135 | 34 | 47610 | |||
| 2026-04-29 | 6-K | 1ST QUARTER RESULTS | 0001654954-26-004047 | 001-11960 | 26910533 | 34 | 1306144 | |||
| 2026-04-28 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0002100119-26-000022 | 005-55247 | 26905011 | 34 | 7683 | |||
| 2026-04-28 | 6-K | BREZTRI APPROVED IN THE US FOR ASTHMA | 0001654954-26-003979 | 001-11960 | 26903150 | 34 | 43431 | |||
| 2026-04-27 | 6-K | SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US | 0001654954-26-003936 | 001-11960 | 26896427 | 34 | 62818 | |||
| 2026-04-23 | 6-K | DIRECTORATE CHANGE | 0001654954-26-003818 | 001-11960 | 26885401 | 34 | 19580 | |||
| 2026-04-21 | 6-K | I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT | 0001654954-26-003757 | 001-11960 | 26876667 | 34 | 45808 | |||
| 2026-04-20 | 6-K | THIRD TOZORAKIMAB POSITIVE PHASE III IN COPD | 0001654954-26-003703 | 001-11960 | 26873336 | 34 | 48096 | |||
| 2026-04-09 | 6-K | RESULT OF AGM | 0001654954-26-003374 | 001-11960 | 26850724 | 34 | 135423 | |||
| 2026-04-08 | 25-NSE | xslF25X02/primary_doc.xml | 0000876661-26-000343 | 001-11960 | 26847566 | 34 | 3810 | |||
| 2026-04-02 | 6-K | IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER | 0001654954-26-003206 | 001-11960 | 26830964 | 34 | 57911 | |||
| 2026-04-01 | 6-K | TOTAL VOTING RIGHTS AND ADMISSION OF SHARES | 0001654954-26-003157 | 001-11960 | 26825447 | 34 | 42290 | |||
| 2026-03-31 | 6-K | EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS | 0001654954-26-003013 | 001-11960 | 26817060 | 34 | 56279 | |||
| 2026-03-27 | 6-K | TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS | 0001654954-26-002860 | 001-11960 | 26801154 | 34 | 52068 | |||
| 2026-03-20 | 6-K | NOTIFICATION OF ADMISSION OF SHARES | 0001654954-26-002523 | 001-11960 | 26776147 | 34 | 40108 | |||
| 2026-03-19 | 3 | OWNERSHIP DOCUMENT | 0001104659-26-032249 | 8536 | ||||||
| 2026-03-16 | 6-K | IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER | 0001654954-26-002272 | 001-11960 | 26754658 | 34 | 58776 | |||
| 2026-03-10 | 6-K | NOTICE OF AGM | 0001654954-26-002077 | 001-11960 | 26737286 | 34 | 30294 | |||
| 2026-03-10 | 6-K | FORM 6-K | 0001104659-26-025559 | 001-11960 | 26737246 | 34 | 6341592 | |||
| 2026-03-06 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001966 | 001-11960 | 26728519 | 34 | 46656 | |||
| 2026-03-06 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001963 | 001-11960 | 26728480 | 34 | 70541 | |||
| 2026-03-06 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-001961 | 001-11960 | 26728470 | 34 | 72719 | |||
| 2026-03-04 | CERT | NYSE CERTIFICATION | 0000876661-26-000201 | 001-11960 | 26719051 | 34 | 177030 | |||
| 2026-03-03 | 8-A12B | FORM 8-A12B | 0001104659-26-022824 | 001-11960 | 26713776 | 34 | 23292 | |||
| 2026-03-02 | 6-K | FORM 6-K | 0001104659-26-022240 | 001-11960 | 26707494 | 34 | 916240 | |||
| 2026-03-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-001728 | 001-11960 | 26705408 | 34 | 19646 | |||
| 2026-02-27 | 424B2 | 424B2 | 0001104659-26-021545 | 333-278067 | 26699623 | 33 | 1052004 | 1 | 1 | |
| 2026-02-26 | 6-K | ASTRAZENECA PRICES A $2BN BOND OFFERING | 0001654954-26-001589 | 001-11960 | 26681970 | 34 | 24351 | |||
| 2026-02-26 | FWP | FWP | 0001104659-26-019812 | 333-278067 | 26680864 | 34 | 38468 | |||
| 2026-02-25 | 6-K | FILING OF FORM 20-F WITH SEC | 0001654954-26-001536 | 001-11960 | 26675295 | 34 | 18386 | |||
| 2026-02-25 | 424B2 | 424B2 | 0001104659-26-019420 | 333-278067 | 26674335 | 33 | 848482 | |||
| 2026-02-24 | IRANNOTICE | IRANNOTICE | 0001104659-26-019141 | 001-11960 | 26671895 | 34 | 6578 | |||
| 2026-02-24 | 20-F | 20-F | 0001104659-26-019130 | 001-11960 | 26671828 | 34 | 127817049 | 1 | 1 | |
| 2026-02-24 | 6-K | FORM 6-K | 0001104659-26-019110 | 001-11960 | 26671556 | 34 | 24060371 | |||
| 2026-02-24 | 6-K | ANNUAL FINANCIAL REPORT | 0001654954-26-001483 | 001-11960 | 26667404 | 34 | 21534 | |||
| 2026-02-24 | 6-K | DIRECTORATE CHANGE | 0001654954-26-001481 | 001-11960 | 26667398 | 34 | 21967 | |||
| 2026-02-20 | 6-K | FIXED-DURATION CALQUENCE COMBO APPROVED IN US | 0001654954-26-001409 | 001-11960 | 26656623 | 34 | 44133 | |||
| 2026-02-10 | 6-K | FINAL RESULTS | 0001654954-26-001073 | 001-11960 | 26614494 | 34 | 1707501 | |||
| 2026-02-06 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-26-011303 | 9872 | ||||||
| 2026-02-06 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001104659-26-011298 | 42402 | ||||||
| 2026-02-03 | 6-K | UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION | 0001654954-26-000857 | 001-11960 | 26590118 | 34 | 52426 | |||
| 2026-02-02 | S-8 | FORM S-8 | 0001104659-26-009284 | 333-293157 | 26592318 | 33 | 1357766 | 1 | 1 | |
| 2026-02-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-000824 | 001-11960 | 26586876 | 34 | 19872 | |||
| 2026-02-02 | 6-K | IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER | 0001654954-26-000795 | 001-11960 | 26585789 | 34 | 61248 | |||
| 2026-02-02 | 6-K | ASTRAZENECA BEGINS TRADING ON NYSE | 0001654954-26-000792 | 001-11960 | 26585717 | 34 | 23213 | |||
| 2026-01-30 | 25 | FORM 25 | 0001104659-26-008613 | 001-11960 | 26583250 | 34 | 19655 | |||
| 2026-01-30 | 6-K | ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC | 0001654954-26-000730 | 001-11960 | 26580386 | 34 | 32710 | |||
| 2026-01-29 | 6-K | ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 | 0001654954-26-000688 | 001-11960 | 26574894 | 34 | 26133 | |||
| 2026-01-22 | CERT | NYSE CERTIFICATION | 0000876661-26-000055 | 001-11960 | 26552047 | 34 | 181611 | |||
| 2026-01-22 | 8-A12B | 8-A12B | 0001104659-26-005799 | 001-11960 | 26551955 | 34 | 47747 | |||
| 2026-01-22 | CERT | NYSE CERTIFICATION | 0000876661-26-000054 | 001-11960 | 26551697 | 34 | 164661 | |||
| 2026-01-22 | 8-A12B | 8-A12B | 0001104659-26-005772 | 001-11960 | 26551524 | 34 | 13416 | |||
| 2026-01-20 | 6-K | ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE | 0001654954-26-000464 | 001-11960 | 26541130 | 34 | 21267 | |||
| 2026-01-08 | 6-K | AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON | 0001654954-26-000153 | 001-11960 | 26517270 | 34 | 19370 | |||
| 2026-01-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-26-000027 | 001-11960 | 26501268 | 34 | 20449 | |||
| 2025-12-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-014171 | 001-11960 | 251589511 | 34 | 45879 | |||
| 2025-12-22 | 6-K | ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC | 0001654954-25-014166 | 001-11960 | 251589444 | 34 | 62170 | |||
| 2025-12-22 | 6-K | UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB | 0001654954-25-014164 | 001-11960 | 251589414 | 34 | 40386 | |||
| 2025-12-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-014136 | 001-11960 | 251585151 | 34 | 62369 | |||
| 2025-12-16 | 6-K | SUBCUTANEOUS SAPHNELO APPROVED IN EU | 0001654954-25-013974 | 001-11960 | 251573319 | 34 | 57420 | |||
| 2025-12-16 | 6-K | ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC | 0001654954-25-013970 | 001-11960 | 251573309 | 34 | 66439 | |||
| 2025-12-04 | 6-K | HOLDING(S) IN COMPANY | 0001654954-25-013678 | 001-11960 | 251548931 | 34 | 78690 | |||
| 2025-12-01 | 6-K | BLOCK LISTING INTERIM REVIEW | 0001654954-25-013569 | 001-11960 | 251538325 | 34 | 32613 | |||
| 2025-12-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-013567 | 001-11960 | 251538307 | 34 | 20258 | |||
| 2025-11-26 | 6-K | IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER | 0001654954-25-013450 | 001-11960 | 251523793 | 34 | 62395 | |||
| 2025-11-24 | 6-K | ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND | 0001654954-25-013401 | 001-11960 | 251509546 | 34 | 25425 | |||
| 2025-11-20 | 6-K | KOSELUGO (SELUMETINIB) APPROVED IN THE US | 0001654954-25-013317 | 001-11960 | 251501122 | 34 | 42305 | |||
| 2025-11-17 | 6-K | HOLDING(S) IN COMPANY | 0001654954-25-013129 | 001-11960 | 251490278 | 34 | 81049 | |||
| 2025-11-14 | 25-NSE | xslF25X02/primary_doc.xml | 0001354457-25-001137 | 001-11960 | 251486126 | 34 | 3247 | |||
| 2025-11-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-013043 | 001-11960 | 251482174 | 34 | 44836 | |||
| 2025-11-12 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-008803 | 001-11960 | 251474504 | 33 | 4968 | |||
| 2025-11-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-012757 | 001-11960 | 251465253 | 34 | 40170 | |||
| 2025-11-06 | 6-K | 9M AND Q3 2025 RESULTS | 0001654954-25-012630 | 001-11960 | 251456192 | 34 | 1688203 | |||
| 2025-11-03 | 6-K | RESULT OF GENERAL MEETING | 0001654954-25-012502 | 001-11960 | 251443233 | 34 | 35044 | |||
| 2025-11-03 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-012498 | 001-11960 | 251443198 | 34 | 20401 | |||
| 2025-11-03 | 6-K | FORM 6-K | 0001104659-25-105425 | 001-11960 | 251443042 | 34 | 21376965 | |||
| 2025-10-28 | 6-K | DIRECTOR DECLARATION | 0001654954-25-012271 | 001-11960 | 251421889 | 34 | 17761 | |||
| 2025-10-28 | 6-K | KOSELUGO (SELUMETINIB) APPROVED IN THE EU | 0001654954-25-012262 | 001-11960 | 251421489 | 34 | 41333 | |||
| 2025-10-22 | 6-K | TEZSPIRE APPROVED IN EU FOR CRSWNP | 0001654954-25-012040 | 001-11960 | 251408640 | 34 | 54418 | |||
| 2025-10-20 | 6-K | US FDA APPROVES TEZSPIRE IN CRSWNP | 0001654954-25-011951 | 001-11960 | 251402303 | 34 | 62408 | |||
| 2025-10-20 | 6-K | POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO | 0001654954-25-011943 | 001-11960 | 251402283 | 34 | 57209 | |||
| 2025-10-14 | 6-K | AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES | 0001654954-25-011688 | 001-11960 | 251389245 | 34 | 26312 | |||
| 2025-10-07 | 6-K | BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL | 0001654954-25-011529 | 001-11960 | 251378213 | 34 | 51408 | |||
| 2025-10-06 | 6-K | DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 | 0001654954-25-011461 | 001-11960 | 251375606 | 34 | 57058 | |||
| 2025-10-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-011310 | 001-11960 | 251362895 | 34 | 19997 | |||
| 2025-09-29 | 6-K | ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 | 0001654954-25-011177 | 001-11960 | 251352083 | 34 | 62865 | |||
| 2025-09-29 | 6-K | AZN HARMONISES LISTING STRUCTURE | 0001654954-25-011175 | 001-11960 | 251352063 | 34 | 30884 | |||
| 2025-09-29 | 6-K | 6-K | 0001104659-25-094039 | 001-11960 | 251351991 | 34 | 737560 | |||
| 2025-09-25 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-011107 | 001-11960 | 251342488 | 34 | 41372 | |||
| 2025-09-22 | 6-K | KOSELUGO RECOMMENDED FOR EU APPROVAL | 0001654954-25-010969 | 001-11960 | 251328438 | 34 | 41580 | |||
| 2025-09-22 | 6-K | TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP | 0001654954-25-010967 | 001-11960 | 251328433 | 34 | 58862 | |||
| 2025-09-17 | 6-K | SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC | 0001654954-25-010847 | 001-11960 | 251318795 | 34 | 51228 | |||
| 2025-09-17 | 6-K | UPDATE ON RESOLUTE PHASE III TRIAL | 0001654954-25-010845 | 001-11960 | 251318780 | 34 | 41684 | |||
| 2025-09-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-010235 | 001-11960 | 251282853 | 34 | 20246 | |||
| 2025-08-28 | 6-K | HOLDING(S) IN COMPANY | 0001654954-25-010131 | 001-11960 | 251269183 | 34 | 17912 | |||
| 2025-08-26 | 6-K | HOLDING(S) IN COMPANY | 0001654954-25-010040 | 001-11960 | 251255476 | 34 | 77930 | |||
| 2025-08-21 | 6-K | HOLDING(S) IN COMPANY | 0001654954-25-009884 | 001-11960 | 251239088 | 34 | 67894 | |||
| 2025-08-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-009748 | 001-11960 | 251226891 | 34 | 46056 | |||
| 2025-08-15 | 6-K | HOLDING(S) IN COMPANY | 0001654954-25-009692 | 001-11960 | 251222935 | 34 | 69142 | |||
| 2025-08-12 | 6-K | HOLDING(S) IN COMPANY | 0001654954-25-009396 | 001-11960 | 251204997 | 34 | 76082 | |||
| 2025-08-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-008838 | 001-11960 | 251175618 | 34 | 17627 | |||
| 2025-07-29 | 6-K | FORM 6-K | 0001104659-25-071432 | 001-11960 | 251157612 | 34 | 12594635 | 1 | 1 | |
| 2025-07-24 | 6-K | GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS | 0001654954-25-008413 | 001-11960 | 251145770 | 34 | 35640 | |||
| 2025-07-22 | 6-K | ASTRAZENECA PLANS TO INVEST $50BN IN THE US | 0001654954-25-008260 | 001-11960 | 251138632 | 34 | 28300 | |||
| 2025-07-16 | 6-K | UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS | 0001654954-25-008111 | 001-11960 | 251126135 | 34 | 37091 | |||
| 2025-07-14 | 6-K | BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL | 0001654954-25-008010 | 001-11960 | 251120417 | 34 | 49907 | |||
| 2025-07-07 | 6-K | IMFINZI APPROVED IN THE EU FOR BLADDER CANCER | 0001654954-25-007785 | 001-11960 | 251106942 | 34 | 46977 | |||
| 2025-07-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-007604 | 001-11960 | 251094864 | 34 | 20389 | |||
| 2025-06-26 | 11-K | FORM 11-K | 0001683168-25-004771 | 001-11960 | 251079165 | 34 | 240907 | |||
| 2025-06-24 | 6-K | DATROWAY APPROVED IN US FOR EGFRM LUNG CANCER | 0001654954-25-007315 | 001-11960 | 251066643 | 34 | 62966 | |||
| 2025-06-13 | 6-K | ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPC | 0001654954-25-006914 | 001-11960 | 251045311 | 34 | 22370 | |||
| 2025-06-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-006868 | 001-11960 | 251042017 | 34 | 40734 | |||
| 2025-06-06 | 6-K | FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLL | 0001654954-25-006655 | 001-11960 | 251028907 | 34 | 42328 | |||
| 2025-06-02 | 6-K | BLOCK LISTING INTERIM REVIEW | 0001654954-25-006418 | 001-11960 | 251014028 | 34 | 30909 | |||
| 2025-06-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-006414 | 001-11960 | 251013984 | 34 | 17993 | |||
| 2025-05-27 | 6-K | IMFINZI RECOMMENDED IN EU FOR BLADDER CANCER | 0001654954-25-006101 | 001-11960 | 25984098 | 34 | 48703 | |||
| 2025-05-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-006059 | 001-11960 | 25979411 | 34 | 43255 | |||
| 2025-05-21 | 6-K | DIRECTOR DECLARATION | 0001654954-25-005972 | 001-11960 | 25971182 | 34 | 18219 | |||
| 2025-05-20 | 6-K | ACQUISITION OF ESOBIOTEC COMPLETED | 0001654954-25-005901 | 001-11960 | 25966152 | 34 | 25946 | |||
| 2025-05-09 | 6-K | IMFINZI IMPROVED DFS IN EARLY BLADDER CANCER | 0001654954-25-005331 | 001-11960 | 25928971 | 34 | 44769 | |||
| 2025-05-07 | 6-K | ENHERTU IMPROVED PCR IN EARLY-STAGE BREAST CANCER | 0001654954-25-005175 | 001-11960 | 25919677 | 34 | 57503 | |||
| 2025-05-06 | 6-K | CALQUENCE COMBINATION APPROVED IN EU FOR 1L MCL | 0001654954-25-005099 | 001-11960 | 25915608 | 34 | 40262 | |||
| 2025-05-02 | 6-K | BREZTRI MET PRIMARY ENDPOINTS IN PH3 ASTHMA TRIALS | 0001654954-25-005021 | 001-11960 | 25905872 | 34 | 38873 | |||
| 2025-05-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-004975 | 001-11960 | 25901508 | 34 | 48981 | |||
| 2025-05-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-004956 | 001-11960 | 25900795 | 34 | 21217 | |||
| 2025-04-29 | 6-K | FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLL | 0001654954-25-004745 | 001-11960 | 25885161 | 34 | 43329 | |||
| 2025-04-29 | 6-K | UPDATE ON CAPITELLO-280 PHASE III TRIAL | 0001654954-25-004742 | 001-11960 | 25884845 | 34 | 36979 | |||
| 2025-04-29 | 6-K | 1ST QUARTER RESULTS | 0001654954-25-004737 | 001-11960 | 25884755 | 34 | 1323071 | |||
| 2025-04-23 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0002052113-25-001438 | 005-55247 | 25863155 | 34 | 11526 | |||
| 2025-04-22 | 6-K | ENHERTU COMBINATION IMPROVED PFS IN 1L HER2+ MBC | 0001654954-25-004504 | 001-11960 | 25854910 | 34 | 61275 | |||
| 2025-04-11 | 6-K | RESULT OF AGM | 0001654954-25-004150 | 001-11960 | 25830970 | 34 | 135784 | |||
| 2025-04-10 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-033481 | 9519 | ||||||
| 2025-04-04 | 6-K | IMFINZI APPROVED IN EU FOR AEGEAN | 0001654954-25-003896 | 001-11960 | 25812023 | 34 | 56821 | |||
| 2025-04-04 | 6-K | ENHERTU APPROVED IN EU IN POST-ET BREAST CANCER | 0001654954-25-003894 | 001-11960 | 25811935 | 34 | 67854 | |||
| 2025-04-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-003772 | 001-11960 | 25798105 | 34 | 19822 | |||
| 2025-03-31 | 6-K | CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL | 0001654954-25-003590 | 001-11960 | 25788881 | 34 | 44561 | |||
| 2025-03-31 | 6-K | IMFINZI APPROVED IN THE US FOR BLADDER CANCER | 0001654954-25-003589 | 001-11960 | 25788826 | 34 | 53425 | |||
| 2025-03-21 | 6-K | AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING | 0001654954-25-003128 | 001-11960 | 25758611 | 34 | 23326 | |||
| 2025-03-17 | 6-K | ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT | 0001654954-25-002841 | 001-11960 | 25742354 | 34 | 35745 | |||
| 2025-03-17 | 6-K | IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC | 0001654954-25-002839 | 001-11960 | 25742344 | 34 | 54524 | |||
| 2025-03-17 | 6-K | ASTRAZENECA TO ACQUIRE ESOBIOTEC | 0001654954-25-002837 | 001-11960 | 25742336 | 34 | 29878 | |||
| 2025-03-12 | 6-K | HOLDING(S) IN COMPANY | 0001654954-25-002669 | 001-11960 | 25731478 | 34 | 75358 | |||
| 2025-03-07 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-002424 | 001-11960 | 25718067 | 34 | 46890 | |||
| 2025-03-07 | 6-K | NOTICE OF AGM | 0001654954-25-002413 | 001-11960 | 25717559 | 34 | 27050 | |||
| 2025-03-07 | 6-K | IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER | 0001654954-25-002412 | 001-11960 | 25717557 | 34 | 60646 | |||
| 2025-03-07 | 6-K | FORM 6-K | 0001104659-25-021517 | 001-11960 | 25717511 | 34 | 6060551 | |||
| 2025-03-06 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-002350 | 001-11960 | 25714105 | 34 | 115910 | |||
| 2025-03-05 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-25-002308 | 001-11960 | 25709332 | 34 | 71846 | |||
| 2025-03-03 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-002199 | 001-11960 | 25694859 | 34 | 19892 | |||
| 2025-03-03 | 6-K | IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN | 0001654954-25-002166 | 001-11960 | 25693507 | 34 | 55073 | |||
| 2025-02-28 | 6-K | ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCER | 0001654954-25-002102 | 001-11960 | 25683266 | 34 | 69253 | |||
| 2025-02-26 | 6-K | CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCER | 0001654954-25-001920 | 001-11960 | 25665931 | 34 | 47026 | |||
| 2025-02-19 | 6-K | FILING OF FORM 20-F WITH SEC | 0001654954-25-001661 | 001-11960 | 25637139 | 34 | 18546 | |||
| 2025-02-18 | IRANNOTICE | IRANNOTICE | 0001104659-25-014758 | 001-11960 | 25634900 | 34 | 6915 | |||
| 2025-02-18 | 20-F | FORM 20-F | 0001104659-25-014750 | 001-11960 | 25634866 | 34 | 147240282 | 1 | 1 | |
| 2025-02-18 | 6-K | FORM 6-K | 0001104659-25-014732 | 001-11960 | 25634750 | 34 | 24533305 | |||
| 2025-02-18 | 6-K | HOLDING(S) IN COMPANY | 0001654954-25-001625 | 001-11960 | 25633304 | 34 | 66742 | |||
| 2025-02-18 | 6-K | ANNUAL FINANCIAL REPORT | 0001654954-25-001619 | 001-11960 | 25632784 | 34 | 21991 | |||
| 2025-02-18 | 6-K | DIRECTORATE CHANGE | 0001654954-25-001614 | 001-11960 | 25632757 | 34 | 25555 | |||
| 2025-02-06 | 6-K | FINAL RESULTS | 0001654954-25-001189 | 001-11960 | 25595803 | 34 | 1754956 | |||
| 2025-02-05 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-25-000324 | 333-284374 | 25595215 | 33 | 1892 | ||
| 2025-02-03 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-001087 | 001-11960 | 25581617 | 34 | 19788 | |||
| 2025-02-03 | 6-K | IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC | 0001654954-25-001005 | 001-11960 | 25580494 | 34 | 56157 | |||
| 2025-01-28 | 6-K | ENHERTU APPROVED IN US FOR BREAST CANCER POST ET | 0001654954-25-000846 | 001-11960 | 25561246 | 34 | 69661 | |||
| 2025-01-24 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001104659-25-005814 | 14466 | ||||||
| 2025-01-21 | F-6 | e664152_f6-az.htm | 0001193805-25-000067 | 333-284374 | 25541411 | 33 | 472128 | |||
| 2025-01-21 | 6-K | DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER | 0001654954-25-000565 | 001-11960 | 25540382 | 34 | 51233 | |||
| 2025-01-17 | 6-K | CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL | 0001654954-25-000518 | 001-11960 | 25537003 | 34 | 47063 | |||
| 2025-01-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-25-000031 | 001-11960 | 25500585 | 34 | 19488 | |||
| 2024-12-26 | 6-K | DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU | 0001654954-24-015891 | 001-11960 | 241578726 | 34 | 42667 | |||
| 2024-12-23 | 6-K | TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL | 0001654954-24-015839 | 001-11960 | 241571683 | 34 | 52215 | |||
| 2024-12-16 | 6-K | DIRECTORATE CHANGE | 0001654954-24-015567 | 001-11960 | 241550399 | 34 | 27654 | |||
| 2024-12-05 | 6-K | IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC | 0001654954-24-015165 | 001-11960 | 241527683 | 34 | 55153 | |||
| 2024-12-04 | 6-K | ASTRAZENECA APPOINTS ISKRA REIC EVP INTERNATIONAL | 0001654954-24-015151 | 001-11960 | 241525044 | 34 | 22562 | |||
| 2024-12-02 | 6-K | BLOCK LISTING INTERIM REVIEW | 0001654954-24-015049 | 001-11960 | 241517727 | 34 | 34455 | |||
| 2024-12-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-24-015048 | 001-11960 | 241517715 | 34 | 21197 | |||
| 2024-11-25 | 6-K | TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER | 0001654954-24-014843 | 001-11960 | 241491886 | 34 | 41767 | |||
| 2024-11-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-014697 | 001-11960 | 241478827 | 34 | 44444 | |||
| 2024-11-18 | 6-K | TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA | 0001654954-24-014570 | 001-11960 | 241469683 | 34 | 52900 | |||
| 2024-11-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-014517 | 001-11960 | 241466018 | 34 | 46679 | |||
| 2024-11-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-014508 | 001-11960 | 241465818 | 34 | 48602 | |||
| 2024-11-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-014235 | 001-11960 | 241452648 | 34 | 48216 | |||
| 2024-11-12 | 6-K | ASTRAZENECA INVESTS $3.5 BILLION IN US | 0001654954-24-014095 | 001-11960 | 241443437 | 34 | 25182 | |||
| 2024-11-12 | 6-K | KOMET PHASE III TRIAL MET PRIMARY ENDPOINT | 0001654954-24-014093 | 001-11960 | 241443406 | 34 | 44541 | |||
| 2024-11-12 | 6-K | 9M AND Q3 2024 RESULTS | 0001654954-24-014089 | 001-11960 | 241443352 | 34 | 1796492 | |||
| 2024-11-12 | 6-K | DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN | 0001654954-24-014084 | 001-11960 | 241443234 | 34 | 56797 | |||
| 2024-11-08 | 6-K | TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS | 0001654954-24-013972 | 001-11960 | 241438199 | 34 | 60267 | |||
| 2024-11-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-24-013617 | 001-11960 | 241417931 | 34 | 19964 | |||
| 2024-10-30 | 6-K | AZN CHINA PRESIDENT UNDER INVESTIGATION | 0001654954-24-013471 | 001-11960 | 241407735 | 34 | 18955 | |||
| 2024-10-28 | SC 13G | SC 13G | 0001104659-24-111584 | 62629 | ||||||
| 2024-10-21 | 6-K | FORM 6-K | 0001654954-24-013146 | 001-11960 | 241382220 | 34 | 44055 | |||
| 2024-10-11 | SC 13G | SC 13G | 0001104659-24-107836 | 55659 | ||||||
| 2024-10-07 | 6-K | ASTRAZENECA LICENSES LIPID LOWERING LP(A) ASSET | 0001654954-24-012726 | 001-11960 | 241356110 | 34 | 31791 | |||
| 2024-10-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-24-012560 | 001-11960 | 241341774 | 34 | 19668 | |||
| 2024-09-26 | 6-K | TAGRISSO US APPROVAL IN UNRESECTABLE LUNG CANCER | 0001654954-24-012321 | 001-11960 | 241326153 | 34 | 51360 | |||
| 2024-09-23 | 6-K | FASENRA RECOMMENDED FOR EU APPROVAL IN EGPA | 0001654954-24-012148 | 001-11960 | 241314593 | 34 | 49051 | |||
| 2024-09-23 | 6-K | FINAL OS RESULTS REPORTED FOR TROPION - BREAST01 | 0001654954-24-012146 | 001-11960 | 241314577 | 34 | 52038 | |||
| 2024-09-20 | 6-K | FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US | 0001654954-24-012136 | 001-11960 | 241312769 | 34 | 37719 | |||
| 2024-09-18 | 6-K | FASENRA EGPA US FDA APPROVAL | 0001654954-24-012038 | 001-11960 | 241306151 | 34 | 56484 | |||
| 2024-09-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-011899 | 001-11960 | 241296779 | 34 | 42324 | |||
| 2024-09-03 | 6-K | TOTAL VOTING RIGHTS | 0001654954-24-011365 | 001-11960 | 241271779 | 34 | 18992 | |||
| 2024-08-16 | 6-K | IMFINZI APPROVED IN US FOR RESECTABLE LUNG CANCER | 0001654954-24-010777 | 001-11960 | 241214072 | 34 | 55359 | |||
| 2024-08-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-24-009768 | 001-11960 | 241164855 | 34 | 19745 | |||
| 2024-07-30 | 6-K | ASTRAZENECA PRICES A EUR1.4BN BOND OFFERING | 0001654954-24-009571 | 001-11960 | 241154311 | 34 | 24014 | |||
| 2024-07-29 | 6-K | CALQUENCE FIXED-DURATION COMBO IMPROVED 1L CLL PFS | 0001654954-24-009496 | 001-11960 | 241148655 | 34 | 39844 | |||
| 2024-07-26 | 6-K | ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER | 0001654954-24-009439 | 001-11960 | 241143520 | 34 | 49581 | |||
| 2024-07-25 | 6-K | FORM 6K | 0001104659-24-082531 | 001-11960 | 241140159 | 34 | 14086577 | 1 | 1 | |
| 2024-07-15 | 6-K | ACQUISITION OF AMOLYT PHARMA COMPLETED | 0001654954-24-008909 | 001-11960 | 241115809 | 34 | 32400 | |||
| 2024-07-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-24-008432 | 001-11960 | 241088647 | 34 | 19230 | |||
| 2024-07-01 | 6-K | LYNPARZA & IMFINZI POSITIVE CHMP IN ENDOMETRIAL | 0001654954-24-008387 | 001-11960 | 241087977 | 34 | 61205 | |||
| 2024-06-26 | 11-K | ANNUAL REPORT | 0001683168-24-004498 | 001-11960 | 241074360 | 34 | 209946 | |||
| 2024-06-25 | 6-K | UPDATE ON IMFINZI ADJUVANT BR.31 TRIAL | 0001654954-24-008130 | 001-11960 | 241066102 | 34 | 52108 | |||
| 2024-06-25 | 6-K | IMFINZI IMPROVED EFS AND OS IN BLADDER CANCER | 0001654954-24-008126 | 001-11960 | 241066094 | 34 | 46635 | |||
| 2024-06-18 | 6-K | UPDATE ON CAPITELLO-290 PHASE III TRIAL | 0001654954-24-007869 | 001-11960 | 241050143 | 34 | 46245 | |||
| 2024-06-17 | 6-K | IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER | 0001654954-24-007805 | 001-11960 | 241046903 | 34 | 52138 | |||
| 2024-06-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-007632 | 001-11960 | 241037676 | 34 | 47161 | |||
| 2024-06-04 | 6-K | FORM 6-K | 0001104659-24-068260 | 001-11960 | 241018414 | 34 | 25649 | |||
| 2024-06-04 | 25-NSE | xslF25X02/primary_doc.xml | 0001354457-24-000385 | 001-11960 | 241016302 | 34 | 3216 | |||
| 2024-06-03 | 6-K | BLOCK LISTING INTERIM REVIEW | 0001654954-24-007202 | 001-11960 | 241012362 | 34 | 32392 | |||
| 2024-06-03 | 6-K | TOTAL VOTING RIGHTS | 0001654954-24-007199 | 001-11960 | 241012345 | 34 | 19979 | |||
| 2024-06-03 | 6-K | TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU | 0001654954-24-007172 | 001-11960 | 241011936 | 34 | 50426 | |||
| 2024-05-28 | 6-K | DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER | 0001654954-24-006926 | 001-11960 | 24986194 | 34 | 50234 | |||
| 2024-05-21 | 6-K | ASTRAZENECA TO DELIVER $80BN REVENUE BY 2030 | 0001654954-24-006698 | 001-11960 | 24966776 | 34 | 39256 | |||
| 2024-05-20 | 6-K | ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE | 0001654954-24-006631 | 001-11960 | 24962302 | 34 | 23938 | |||
| 2024-05-16 | 6-K | SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT | 0001654954-24-006451 | 001-11960 | 24953526 | 34 | 34032 | |||
| 2024-05-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-006324 | 001-11960 | 24947912 | 34 | 45396 | |||
| 2024-05-07 | 6-K | ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT | 0001654954-24-005658 | 001-11960 | 24919620 | 34 | 26851 | |||
| 2024-05-02 | 6-K | CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL | 0001654954-24-005422 | 001-11960 | 24905144 | 34 | 41908 | |||
| 2024-05-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-24-005359 | 001-11960 | 24900827 | 34 | 18741 | |||
| 2024-04-29 | 6-K | TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL | 0001654954-24-005107 | 001-11960 | 24886585 | 34 | 66185 | |||
| 2024-04-29 | 6-K | ENHERTU IMPROVED PFS IN HER2-LOW AND ULTRALOW | 0001654954-24-005105 | 001-11960 | 24886524 | 34 | 56475 | |||
| 2024-04-25 | 6-K | 1ST QUARTER RESULTS | 0001654954-24-004975 | 001-11960 | 24872745 | 34 | 1367259 | |||
| 2024-04-11 | 6-K | RESULT OF AGM | 0001654954-24-004501 | 001-11960 | 24837877 | 34 | 140563 | |||
| 2024-04-11 | 6-K | ASTRAZENECA INCREASES 2024 DIVIDEND BY 7% | 0001654954-24-004470 | 001-11960 | 24837098 | 34 | 22554 | |||
| 2024-04-08 | 6-K | ENHERTU APPROVED IN US FOR HER2+ SOLID TUMOURS | 0001654954-24-004314 | 001-11960 | 24828037 | 34 | 69279 | |||
| 2024-04-05 | 6-K | IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC | 0001654954-24-004274 | 001-11960 | 24824701 | 34 | 52721 | |||
| 2024-04-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-24-004141 | 001-11960 | 24813159 | 34 | 20286 | |||
| 2024-04-02 | 6-K | VOYDEYA APPROVED IN US | 0001654954-24-004088 | 001-11960 | 24812332 | 34 | 48597 | |||
| 2024-04-02 | 6-K | FDA ACCEPTS DATO-DXD BLA FOR BREAST CANCER | 0001654954-24-004084 | 001-11960 | 24812252 | 34 | 46251 | |||
| 2024-03-25 | 6-K | ULTOMIRIS APPROVED IN THE US FOR NMOSD | 0001654954-24-003566 | 001-11960 | 24776882 | 34 | 55187 | |||
| 2024-03-19 | DFAN14A | DFAN14A | 0001104659-24-036230 | 2907659 | ||||||
| 2024-03-19 | F-3ASR | F-3ASR | 0001104659-24-036178 | 333-278067 | 24763902 | 33 | 971941 | |||
| 2024-03-19 | 6-K | FORM 6-K | 0001104659-24-035786 | 001-11960 | 24760981 | 34 | 34208 | |||
| 2024-03-14 | 6-K | ASTRAZENECA TO ACQUIRE AMOLYT | 0001654954-24-003100 | 001-11960 | 24747909 | 34 | 39205 | |||
| 2024-03-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-002957 | 001-11960 | 24740187 | 34 | 49250 | |||
| 2024-03-07 | 6-K | FORM 6-K | 0001104659-24-031683 | 001-11960 | 24728065 | 34 | 5602200 | |||
| 2024-03-07 | 6-K | NOTICE OF AGM | 0001654954-24-002749 | 001-11960 | 24728063 | 34 | 27080 | |||
| 2024-03-06 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-002690 | 001-11960 | 24724628 | 34 | 45296 | |||
| 2024-03-06 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-002688 | 001-11960 | 24724616 | 34 | 69623 | |||
| 2024-03-06 | CERT | AZN_8A_Cert_Notes.pdf | 0001354457-24-000128 | 001-11960 | 24724369 | 34 | 280073 | |||
| 2024-03-05 | 8-A12B | 8-A12B | 0001104659-24-031066 | 001-11960 | 24721398 | 34 | 26000 | |||
| 2024-03-04 | 6-K | EMA VALIDATES DATO-DXD MAAS FOR NSQ NSCLC AND BC | 0001654954-24-002518 | 001-11960 | 24712790 | 34 | 46647 | |||
| 2024-03-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-24-002477 | 001-11960 | 24707835 | 34 | 19837 | |||
| 2024-02-26 | 6-K | FORM 6-K | 0001104659-24-027496 | 001-11960 | 24678674 | 34 | 1449996 | |||
| 2024-02-26 | 6-K | VOYDEYA RECOMMENDED FOR EU APPROVAL | 0001654954-24-002155 | 001-11960 | 24673473 | 34 | 49413 | |||
| 2024-02-23 | 424B2 | 424B2 | 0001104659-24-027015 | 333-256406 | 24671220 | 33 | 960084 | |||
| 2024-02-22 | 6-K | ASTRAZENECA PRICES A $5BN BOND OFFERING | 0001654954-24-002042 | 001-11960 | 24662544 | 34 | 26576 | |||
| 2024-02-22 | 6-K | FORM 6-K | 0001104659-24-026359 | 001-11960 | 24662518 | 34 | 25358 | |||
| 2024-02-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-24-002028 | 001-11960 | 24662175 | 34 | 46543 | |||
| 2024-02-22 | FWP | FWP | 0001104659-24-026163 | 333-256406 | 24661712 | 34 | 49055 | |||
| 2024-02-21 | SC TO-T/A | SC TO-T/A | 0001104659-24-025822 | 29961 | ||||||
| 2024-02-21 | 424B2 | 424B2 | 0001104659-24-025819 | 333-256406 | 24656447 | 33 | 900411 | |||
| 2024-02-21 | 6-K | FILING OF FORM 20-F WITH SEC | 0001654954-24-001982 | 001-11960 | 24656290 | 34 | 19066 | |||
| 2024-02-20 | S-8 | FORM S-8 | 0001104659-24-025610 | 333-277197 | 24654943 | 33 | 176566 | |||
| 2024-02-20 | IRANNOTICE | IRANNOTICE | 0001104659-24-025568 | 001-11960 | 24654066 | 34 | 7451 | |||
| 2024-02-20 | 20-F | FORM 20-F | 0001104659-24-025553 | 001-11960 | 24654013 | 34 | 140839360 | 1 | 1 | |
| 2024-02-20 | 6-K | FORM 6-K | 0001104659-24-025540 | 001-11960 | 24653673 | 34 | 18449803 | |||
| 2024-02-20 | 6-K | ANNUAL FINANCIAL REPORT | 0001654954-24-001937 | 001-11960 | 24651167 | 34 | 25218 | |||
| 2024-02-20 | SC TO-T/A | SC TO-T/A | 0001104659-24-025223 | 73208 | ||||||
| 2024-02-20 | 6-K | FORM 6-K | 0001104659-24-025224 | 001-11960 | 24650761 | 34 | 34508 | |||
| 2024-02-20 | 6-K | ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX | 0001654954-24-001914 | 001-11960 | 24650688 | 34 | 45816 | |||
| 2024-02-20 | 6-K | TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER | 0001654954-24-001908 | 001-11960 | 24650647 | 34 | 48760 | |||
| 2024-02-20 | 6-K | FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC | 0001654954-24-001903 | 001-11960 | 24650641 | 34 | 44768 | |||
| 2024-02-20 | 6-K | TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER | 0001654954-24-001899 | 001-11960 | 24650602 | 34 | 46070 | |||
| 2024-02-15 | SC TO-T/A | SC TO-T/A | 0001104659-24-024104 | 33004 | ||||||
| 2024-02-12 | SC 13G/A | SC 13G/A | 0001104659-24-013882 | 58087 | ||||||
| 2024-02-08 | 6-K | FINAL RESULTS | 0001654954-24-001467 | 001-11960 | 24606794 | 34 | 1917570 | |||
| 2024-02-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-24-001173 | 001-11960 | 24585423 | 34 | 19954 | |||
| 2024-01-24 | SC 13G/A | gb0009895292_012424.txt | 0001086364-24-002650 | 005-55247 | 24557742 | 34 | 14201 | |||
| 2024-01-19 | SC TO-T/A | SC TO-T/A | 0001104659-24-005033 | 43101 | ||||||
| 2024-01-19 | 6-K | FORM 6-K | 0001104659-24-005026 | 001-11960 | 24543807 | 34 | 24039 | |||
| 2024-01-11 | SC TO-T/A | SC TO-T/A | 0001104659-24-003090 | 75647 | ||||||
| 2024-01-10 | CORRESP | filename1.htm | 0001104659-24-003086 | 64882 | ||||||
| 2024-01-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-24-000032 | 001-11960 | 24500899 | 34 | 19431 | |||
| 2023-12-27 | SC TO-T | SC TO-T | 0001104659-23-129493 | 5653434 | ||||||
| 2023-12-27 | 6-K | ASTRAZENECA ACQUIRES GRACELL | 0001654954-23-015982 | 001-11960 | 231514594 | 34 | 42196 | |||
| 2023-12-26 | 6-K | FORM 6-K | 0001104659-23-129281 | 001-11960 | 231514181 | 34 | 33933 | |||
| 2023-12-22 | 6-K | WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL | 0001654954-23-015901 | 001-11960 | 231507114 | 34 | 43472 | |||
| 2023-12-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-23-015521 | 001-11960 | 231485880 | 34 | 44898 | |||
| 2023-12-12 | SC TO-C | SC TO-C | 0001104659-23-125421 | 93499 | ||||||
| 2023-12-12 | 6-K | FORM 6-K | 0001104659-23-125420 | 001-11960 | 231482051 | 34 | 43151 | |||
| 2023-12-12 | 6-K | ASTRAZENECA TO ACQUIRE ICOSAVAX | 0001654954-23-015390 | 001-11960 | 231479910 | 34 | 50767 | |||
| 2023-12-01 | 6-K | BLOCK LISTING INTERIM REVIEW | 0001654954-23-015044 | 001-11960 | 231458169 | 34 | 35700 | |||
| 2023-12-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-23-015043 | 001-11960 | 231458158 | 34 | 21476 | |||
| 2023-12-01 | 6-K | DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS | 0001654954-23-015010 | 001-11960 | 231457475 | 34 | 43041 | |||
| 2023-11-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-23-014734 | 001-11960 | 231435006 | 34 | 72838 | |||
| 2023-11-17 | 6-K | TRUQAP APPROVED IN US FOR HR+ BREAST CANCER | 0001654954-23-014510 | 001-11960 | 231416395 | 34 | 54414 | |||
| 2023-11-16 | SC 13D/A | SC 13D/A | 0001104659-23-118991 | 48065 | ||||||
| 2023-11-14 | 25-NSE | xslF25X02/primary_doc.xml | 0001354457-23-000837 | 001-11960 | 231406594 | 34 | 3103 | |||
| 2023-11-14 | 6-K | UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI | 0001654954-23-014199 | 001-11960 | 231401465 | 34 | 48561 | |||
| 2023-11-13 | 144 | xsl144X01/primary_doc.xml | 0001104659-23-116769 | 001-11960 | 231395336 | 33 | 6705 | |||
| 2023-11-09 | SC 13D | SC 13D | 0001104659-23-116366 | 96935 | ||||||
| 2023-11-09 | 6-K | DIRECTOR DECLARATION | 0001654954-23-013975 | 001-11960 | 231390498 | 34 | 21459 | |||
| 2023-11-09 | 6-K | IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER | 0001654954-23-013973 | 001-11960 | 231390478 | 34 | 56457 | |||
| 2023-11-09 | 6-K | AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA | 0001654954-23-013971 | 001-11960 | 231390463 | 34 | 26798 | |||
| 2023-11-09 | 6-K | 9M AND Q3 2023 RESULTS | 0001654954-23-013969 | 001-11960 | 231390442 | 34 | 1949503 | |||
| 2023-11-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-23-013666 | 001-11960 | 231367317 | 34 | 18924 | |||
| 2023-11-01 | 6-K | ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS | 0001654954-23-013630 | 001-11960 | 231366477 | 34 | 28280 | |||
| 2023-10-03 | 6-K | ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS | 0001654954-23-012523 | 001-11960 | 231301562 | 34 | 23543 | |||
| 2023-10-02 | 6-K | TOTAL VOTING RIGHTS | 0001654954-23-012469 | 001-11960 | 231298260 | 34 | 19979 | |||
| 2023-09-25 | 6-K | DATO-DXD IMPROVED PFS IN BREAST CANCER | 0001654954-23-012206 | 001-11960 | 231274363 | 34 | 47243 | |||
| 2023-09-20 | 6-K | ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT | 0001654954-23-012050 | 001-11960 | 231265285 | 34 | 21473 | |||
| 2023-09-15 | 6-K | ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC | 0001654954-23-011919 | 001-11960 | 231257115 | 34 | 56312 | |||
| 2023-09-11 | 6-K | FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT | 0001654954-23-011717 | 001-11960 | 231247111 | 34 | 49581 | |||
| 2023-09-06 | 6-K | UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD | 0001654954-23-011565 | 001-11960 | 231237824 | 34 | 49120 | |||
| 2023-09-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-23-011460 | 001-11960 | 231230997 | 34 | 18849 | |||
| 2023-08-16 | 25-NSE | xslF25X02/primary_doc.xml | 0001354457-23-000587 | 001-11960 | 231178300 | 34 | 3135 | |||
| 2023-08-01 | 6-K | TOTAL VOTING RIGHTS | 0001654954-23-009946 | 001-11960 | 231130547 | 34 | 20011 | |||
| 2023-07-28 | 6-K | FORM 6K | 0001104659-23-085104 | 001-11960 | 231120334 | 34 | 13871725 | 1 | 1 | |
| 2023-07-28 | 6-K | ALEXION ENTERS GENE THERAPY AGREEMENT WITH PFIZER | 0001654954-23-009766 | 001-11960 | 231120121 | 34 | 26872 | |||
| 2023-07-17 | 6-K | BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTION | 0001654954-23-009256 | 001-11960 | 231091296 | 34 | 53952 | |||
| 2023-07-03 | 6-K | TOTAL VOTING RIGHTS | 0001654954-23-008686 | 001-11960 | 231064540 | 34 | 19668 | |||
| 2023-07-03 | 6-K | DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCER | 0001654954-23-008655 | 001-11960 | 231063734 | 34 | 48105 | |||
| 2023-06-28 | 11-K | ANNUAL REPORT | 0001683168-23-004490 | 001-11960 | 231053375 | 34 | 196950 | |||
| 2023-06-09 | 6-K | NIRSEVIMAB RECOMMENDED FOR INFANT RSV PROTECTION | 0001654954-23-007833 | 001-11960 | 231003835 | 34 | 74697 | |||
| 2023-06-09 | 6-K | ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICS | 0001654954-23-007832 | 001-11960 | 231003822 | 34 | 27028 | |||
| 2023-06-02 | 6-K | IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERS | 0001654954-23-007542 | 001-11960 | 23987431 | 34 | 56634 |
One latest value per concept from companyfacts (375 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ifrs-full | AccountingProfit | AccountingProfit | USD | 12.40B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AccrualsClassifiedAsCurrent | AccrualsClassifiedAsCurrent | USD | 7.26B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | AccrualsClassifiedAsNoncurrent | AccrualsClassifiedAsNoncurrent | USD | 85.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | AcquisitionsThroughBusinessCombinationsOtherProvisions | AcquisitionsThroughBusinessCombinationsOtherProvisions | USD | 50.00M | 2024-01-01 | 2024-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment | AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment | USD | 1.14B | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 |
| ifrs-full | ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsBeforeTaxDefinedBenefitPlans | ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsBeforeTaxDefinedBenefitPlans | USD | -74.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsBeforeTaxDefinedBenefitPlans | ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsBeforeTaxDefinedBenefitPlans | USD | 220.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ActuarialGainsLossesArisingFromExperienceAdjustmentsBeforeTaxDefinedBenefitPlans | ActuarialGainsLossesArisingFromExperienceAdjustmentsBeforeTaxDefinedBenefitPlans | USD | 59.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AdditionalLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination | AdditionalLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination | USD | 198.00M | 2024-01-01 | 2024-06-30 | 2025 | Q2 | 6-K | 2025-07-29 | 0001104659-25-071432 |
| ifrs-full | AdjustedWeightedAverageShares | AdjustedWeightedAverageShares | shares | 1.56B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AdjustmentsForCurrentTaxOfPriorPeriod | AdjustmentsForCurrentTaxOfPriorPeriod | USD | -60.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AdjustmentsForDecreaseIncreaseInInventories | AdjustmentsForDecreaseIncreaseInInventories | USD | -755.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables | AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables | USD | -1.73B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AdjustmentsForDeferredTaxOfPriorPeriods | AdjustmentsForDeferredTaxOfPriorPeriods | USD | -47.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss | AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss | USD | 5.73B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AdjustmentsForFinanceIncomeCost | AdjustmentsForFinanceIncomeCost | USD | -1.33B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates | AdjustmentsForGainLossOnDisposalOfInvestmentsInSubsidiariesJointVenturesAndAssociates | USD | 776.00M | 2021-01-01 | 2021-12-31 | 2023 | FY | 20-F | 2024-02-20 | 0001104659-24-025553 |
| ifrs-full | AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment | AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment | USD | -13.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives | AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives | USD | -172.00M | 2019-01-01 | 2019-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 |
| ifrs-full | AdjustmentsForSharebasedPayments | AdjustmentsForSharebasedPayments | USD | 719.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod | AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod | USD | -7.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AdjustmentsForUnrealisedForeignExchangeLossesGains | AdjustmentsForUnrealisedForeignExchangeLossesGains | USD | 201.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans | AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans | USD | 5.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AllowanceAccountForCreditLossesOfFinancialAssets | AllowanceAccountForCreditLossesOfFinancialAssets | USD | 59.00M | 2022-12-31 | 2022 | FY | 20-F | 2023-02-21 | 0001104659-23-023818 | |
| ifrs-full | AmortisationIntangibleAssetsOtherThanGoodwill | AmortisationIntangibleAssetsOtherThanGoodwill | USD | 4.21B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AmountsPayableToTransfereeInRespectOfTransferredAssets | AmountsPayableToTransfereeInRespectOfTransferredAssets | USD | 1.59B | 2022-06-30 | 2022 | Q2 | 6-K | 2022-07-29 | 0001104659-22-083922 | |
| ifrs-full | ApplicableTaxRate | ApplicableTaxRate | pure | 0.25 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | Assets | Assets | USD | 114.07B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | AverageEffectiveTaxRate | AverageEffectiveTaxRate | pure | 0.18 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | AverageNumberOfEmployees | AverageNumberOfEmployees | employee | 95,100 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | BalancesWithBanks | BalancesWithBanks | USD | 5.80B | 2023-12-31 | 2023 | FY | 20-F | 2024-02-20 | 0001104659-24-025553 | |
| ifrs-full | BankOverdraftsClassifiedAsCashEquivalents | BankOverdraftsClassifiedAsCashEquivalents | USD | 13.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | BasicEarningsLossPerShare | BasicEarningsLossPerShare | USD/shares | 6.6 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | Borrowings | Borrowings | USD | 29.62B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | BorrowingsInterestRate | BorrowingsInterestRate | pure | 0.03 | 2019-01-01 | 2020 | FY | 20-F | 2021-02-16 | 0001104659-21-022456 | |
| ifrs-full | CapitalRedemptionReserve | CapitalRedemptionReserve | USD | 153.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | Cash | Cash | USD | 1.33B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CashAndCashEquivalents | CashAndCashEquivalents | USD | 5.71B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets | CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets | USD | 1.07B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition | CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition | USD | 5.70B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CashCollateralPledgedSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities | CashCollateralPledgedSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities | USD | 465.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CashCollateralReceivedSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets | CashCollateralReceivedSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets | USD | 465.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CashFlowsFromUsedInFinancingActivities | CashFlowsFromUsedInFinancingActivities | USD | -7.54B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings | CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowings | USD | 364.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | CashFlowsFromUsedInInvestingActivities | CashFlowsFromUsedInInvestingActivities | USD | -6.81B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | CashFlowsFromUsedInOperatingActivities | CashFlowsFromUsedInOperatingActivities | USD | 14.57B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | CashFlowsFromUsedInOperations | CashFlowsFromUsedInOperations | USD | 18.74B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities | CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities | USD | 2.77B | 2024-01-01 | 2024-06-30 | 2025 | Q2 | 6-K | 2025-07-29 | 0001104659-25-071432 |
| ifrs-full | CashOutflowForLeases | CashOutflowForLeases | USD | 452.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | CashTransferred | CashTransferred | USD | 1.50B | 2017-12-31 | 2017 | FY | 20-F | 2018-03-06 | 0001104659-18-015257 | |
| ifrs-full | ChangesInEquity | ChangesInEquity | USD | 7.85B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ClosingForeignExchangeRate | ClosingForeignExchangeRate | CNY/USD | 6.68 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-05 | 0001104659-19-012881 | |
| ifrs-full | ComprehensiveIncome | ComprehensiveIncome | USD | 12.94B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ComprehensiveIncomeAttributableToNoncontrollingInterests | ComprehensiveIncomeAttributableToNoncontrollingInterests | USD | 16.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ComprehensiveIncomeAttributableToOwnersOfParent | ComprehensiveIncomeAttributableToOwnersOfParent | USD | 12.92B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ContingentLiabilitiesRecognisedInBusinessCombination | ContingentLiabilitiesRecognisedInBusinessCombination | USD | 550.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | ContractualCapitalCommitments | ContractualCapitalCommitments | USD | 1.73B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CostOfInventoriesRecognisedAsExpenseDuringPeriod | CostOfInventoriesRecognisedAsExpenseDuringPeriod | USD | 7.60B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | CostOfSales | CostOfSales | USD | 10.63B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | CurrentAccruedIncomeOtherThanCurrentContractAssets | CurrentAccruedIncomeOtherThanCurrentContractAssets | USD | 844.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentAssets | CurrentAssets | USD | 28.72B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings | CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings | USD | 3.10B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentContractLiabilities | CurrentContractLiabilities | USD | 12.00M | 2020-12-31 | 2020 | FY | 20-F | 2021-02-16 | 0001104659-21-022456 | |
| ifrs-full | CurrentDerivativeFinancialAssets | CurrentDerivativeFinancialAssets | USD | 90.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentDerivativeFinancialLiabilities | CurrentDerivativeFinancialLiabilities | USD | 81.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentFinanceLeaseLiabilities | CurrentFinanceLeaseLiabilities | USD | 5.00M | 2017-12-31 | 2018 | Q2 | 6-K | 2018-07-26 | 0001104659-18-047274 | |
| ifrs-full | CurrentFinancialAssetsAtFairValueThroughProfitOrLoss | CurrentFinancialAssetsAtFairValueThroughProfitOrLoss | USD | 8.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentFinancialAssetsAvailableforsale | CurrentFinancialAssetsAvailableforsale | USD | 1.15B | 2017-12-31 | 2017 | FY | 20-F | 2018-03-06 | 0001104659-18-015257 | |
| ifrs-full | CurrentGovernmentGrants | CurrentGovernmentGrants | USD | 2.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentInvestments | CurrentInvestments | USD | 30.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentLeaseLiabilities | CurrentLeaseLiabilities | USD | 382.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentLiabilities | CurrentLiabilities | USD | 30.62B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax | CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax | USD | 580.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentPortionOfLongtermBorrowings | CurrentPortionOfLongtermBorrowings | USD | 4.46B | 2025-06-30 | 2025 | Q2 | 6-K | 2025-07-29 | 0001104659-25-071432 | |
| ifrs-full | CurrentPrepayments | CurrentPrepayments | USD | 2.03B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentProvisions | CurrentProvisions | USD | 686.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentRawMaterialsAndCurrentProductionSupplies | CurrentRawMaterialsAndCurrentProductionSupplies | USD | 1.86B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentSecuredBankLoansReceivedAndCurrentPortionOfNoncurrentSecuredBankLoansReceived | CurrentSecuredBankLoansReceivedAndCurrentPortionOfNoncurrentSecuredBankLoansReceived | USD | 0 | 2023-12-31 | 2024 | FY | 20-F | 2025-02-18 | 0001104659-25-014750 | |
| ifrs-full | CurrentServiceCostDefinedBenefitPlans | CurrentServiceCostDefinedBenefitPlans | USD | 86.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | CurrentTaxAssets | CurrentTaxAssets | USD | 2.55B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentTaxAssetsCurrent | CurrentTaxAssetsCurrent | USD | 1.16B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentTaxAssetsNoncurrent | CurrentTaxAssetsNoncurrent | USD | 1.39B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentTaxExpenseIncome | CurrentTaxExpenseIncome | USD | 2.42B | 2023-01-01 | 2023-12-31 | 2023 | FY | 20-F | 2024-02-20 | 0001104659-24-025553 |
| ifrs-full | CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods | CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods | USD | 2.33B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes | CurrentTaxExpenseIncomeRelatedToPillarTwoIncomeTaxes | USD | 194.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | CurrentTaxLiabilities | CurrentTaxLiabilities | USD | 1.78B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentTaxLiabilitiesCurrent | CurrentTaxLiabilitiesCurrent | USD | 1.08B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentTaxLiabilitiesNoncurrent | CurrentTaxLiabilitiesNoncurrent | USD | 700.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | CurrentTradeReceivables | CurrentTradeReceivables | USD | 10.24B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsOtherThanGoodwill | DecreaseThroughClassifiedAsHeldForSaleIntangibleAssetsOtherThanGoodwill | USD | 1.50B | 2018-01-01 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-05 | 0001104659-19-012881 |
| ifrs-full | DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised | DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised | USD | 719.00M | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 | |
| ifrs-full | DeferredTaxAssets | DeferredTaxAssets | USD | 5.82B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset | DeferredTaxExpenseArisingFromWritedownOrReversalOfWritedownOfDeferredTaxAsset | USD | 15.00M | 2021-01-01 | 2021-12-31 | 2022 | FY | 20-F | 2023-02-21 | 0001104659-23-023818 |
| ifrs-full | DeferredTaxExpenseIncomeRecognisedInProfitOrLoss | DeferredTaxExpenseIncomeRecognisedInProfitOrLoss | USD | -164.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences | DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences | USD | -117.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | DeferredTaxLiabilities | DeferredTaxLiabilities | USD | 3.50B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | DeferredTaxLiabilityAsset | DeferredTaxLiabilityAsset | USD | -2.32B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity | DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity | USD | -105.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | DefinedBenefitObligationAtPresentValue | DefinedBenefitObligationAtPresentValue | USD | 7.48B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss | DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss | USD | 5.48B | 2022-01-01 | 2022-12-31 | 2022 | FY | 20-F | 2023-02-21 | 0001104659-23-023818 |
| ifrs-full | DepreciationPropertyPlantAndEquipment | DepreciationPropertyPlantAndEquipment | USD | 879.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | DepreciationRightofuseAssets | DepreciationRightofuseAssets | USD | 404.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | DerivativeFinancialAssets | DerivativeFinancialAssets | USD | 145.00M | 2021-06-30 | 2021 | Q2 | 6-K | 2021-07-30 | 0001104659-21-097781 | |
| ifrs-full | DerivativesAmountContributedToFairValueOfPlanAssets | DerivativesAmountContributedToFairValueOfPlanAssets | USD | -355.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets | DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets | USD | 0 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | DilutedEarningsLossPerShare | DilutedEarningsLossPerShare | USD/shares | 6.54 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares | DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares | shares | 12.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | DistributionCosts | DistributionCosts | USD | 579.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | DividendsPaidClassifiedAsFinancingActivities | DividendsPaidClassifiedAsFinancingActivities | USD | 4.97B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | DividendsPaidOrdinaryShares | DividendsPaidOrdinaryShares | USD | 4.85B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | DividendsPaidOrdinarySharesPerShare | DividendsPaidOrdinarySharesPerShare | USD/shares | 1.03 | 2025-09-08 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | DividendsRecognisedAsDistributionsToNoncontrollingInterests | DividendsRecognisedAsDistributionsToNoncontrollingInterests | USD | 6.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | DividendsRecognisedAsDistributionsToOwnersOfParent | DividendsRecognisedAsDistributionsToOwnersOfParent | USD | 4.85B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear | DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToCurrentYear | USD | 1.60B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToPriorYears | DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToPriorYears | USD | 3.25B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | DividendsRecognisedAsDistributionsToOwnersPerShare | DividendsRecognisedAsDistributionsToOwnersPerShare | USD/shares | 3.13 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | EffectOfExchangeRateChangesOnCashAndCashEquivalents | EffectOfExchangeRateChangesOnCashAndCashEquivalents | USD | 46.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | EmployeeBenefitsExpense | EmployeeBenefitsExpense | USD | 14.55B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | Equity | Equity | USD | 48.72B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | EquityAttributableToOwnersOfParent | EquityAttributableToOwnersOfParent | USD | 48.67B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets | ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets | USD | 615.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 |
| ifrs-full | ExpenseFromSharebasedPaymentTransactionsWithEmployees | ExpenseFromSharebasedPaymentTransactionsWithEmployees | USD | 719.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ExpenseOfRestructuringActivities | ExpenseOfRestructuringActivities | USD | 237.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed | ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed | USD | 1.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 |
| ifrs-full | ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed | ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed | USD | 4.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 |
| ifrs-full | ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities | ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities | USD | 4.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 |
| ifrs-full | FinanceCosts | FinanceCosts | USD | 1.69B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | FinanceIncome | FinanceIncome | USD | 360.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | FinanceIncomeCost | FinanceIncomeCost | USD | -1.33B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | FinancialAssets | FinancialAssets | USD | 6.39B | 2022-12-31 | 2022 | FY | 20-F | 2023-02-21 | 0001104659-23-023818 | |
| ifrs-full | FinancialAssetsAtFairValueThroughProfitOrLoss | FinancialAssetsAtFairValueThroughProfitOrLoss | USD | 19.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | FinancialAssetsAvailableforsale | FinancialAssetsAvailableforsale | USD | 2.08B | 2017-12-31 | 2019 | FY | 20-F | 2020-03-03 | 0001104659-20-028557 | |
| ifrs-full | FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome | FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome | USD | 2.21B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets | FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialAssets | USD | 63.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities | FinancialInstrumentsSubjectToEnforceableMasterNettingArrangementOrSimilarAgreementNotSetOffAgainstFinancialLiabilities | USD | 63.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | FinancialLiabilities | FinancialLiabilities | USD | 30.30B | 2024-12-31 | 2024 | FY | 20-F | 2025-02-18 | 0001104659-25-014750 | |
| ifrs-full | FinancialLiabilitiesAtAmortisedCost | FinancialLiabilitiesAtAmortisedCost | USD | 2.15B | 2019-12-31 | 2019 | FY | 20-F | 2020-03-03 | 0001104659-20-028557 | |
| ifrs-full | FinancialLiabilitiesAtFairValue | FinancialLiabilitiesAtFairValue | USD | 29.18B | 2024-12-31 | 2024 | FY | 20-F | 2025-02-18 | 0001104659-25-014750 | |
| ifrs-full | FinishedGoods | FinishedGoods | USD | 1.92B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | GainsLossesOnAvailableforsaleFinancialAssets | GainsLossesOnAvailableforsaleFinancialAssets | USD | 34.00M | 2017-01-01 | 2017-12-31 | 2019 | FY | 20-F | 2020-03-03 | 0001104659-20-028557 |
| ifrs-full | GainsLossesOnCashFlowHedgesBeforeTax | GainsLossesOnCashFlowHedgesBeforeTax | USD | 263.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | GainsLossesOnChangeInFairValueOfDerivatives | GainsLossesOnChangeInFairValueOfDerivatives | USD | -4.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 |
| ifrs-full | GainsLossesOnDisposalsOfNoncurrentAssets | GainsLossesOnDisposalsOfNoncurrentAssets | USD | 25.00M | 2020-01-01 | 2020-12-31 | 2020 | FY | 20-F | 2021-02-16 | 0001104659-21-022456 |
| ifrs-full | GainsLossesOnDisposalsOfOtherNoncurrentAssets | GainsLossesOnDisposalsOfOtherNoncurrentAssets | USD | 25.00M | 2020-01-01 | 2020-12-31 | 2020 | FY | 20-F | 2021-02-16 | 0001104659-21-022456 |
| ifrs-full | GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss | GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss | USD | -218.00M | 2023-01-01 | 2023-12-31 | 2023 | FY | 20-F | 2024-02-20 | 0001104659-24-025553 |
| ifrs-full | GainsLossesOnHedgesOfNetInvestmentsInForeignOperationsBeforeTax | GainsLossesOnHedgesOfNetInvestmentsInForeignOperationsBeforeTax | USD | 40.00M | 2023-01-01 | 2023-06-30 | 2023 | Q2 | 6-K | 2023-07-28 | 0001104659-23-085104 |
| ifrs-full | GainsLossesOnIneffectivenessOfCashFlowHedgesRecognisedInProfitOrLoss | GainsLossesOnIneffectivenessOfCashFlowHedgesRecognisedInProfitOrLoss | USD | 0 | 2017-01-01 | 2017-12-31 | 2017 | FY | 20-F | 2018-03-06 | 0001104659-18-015257 |
| ifrs-full | GainsOnChangeInFairValueOfDerivatives | GainsOnChangeInFairValueOfDerivatives | USD | 113.00M | 2024-01-01 | 2024-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | GainsOnDisposalsOfInvestments | GainsOnDisposalsOfInvestments | USD | 161.00M | 2017-01-01 | 2017-12-31 | 2019 | FY | 20-F | 2020-03-03 | 0001104659-20-028557 |
| ifrs-full | Goodwill | Goodwill | USD | 21.24B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | GoodwillDerecognisedWithoutHavingPreviouslyBeenIncludedInDisposalGroupClassifiedAsHeldForSale | GoodwillDerecognisedWithoutHavingPreviouslyBeenIncludedInDisposalGroupClassifiedAsHeldForSale | USD | 603.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements | GrossFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements | USD | 610.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements | GrossFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements | USD | 554.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | GrossProfit | GrossProfit | USD | 48.11B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ImpairmentLossOnFinancialAssets | ImpairmentLossOnFinancialAssets | USD | 14.00M | 2017-01-01 | 2017-12-31 | 2017 | FY | 20-F | 2018-03-06 | 0001104659-18-015257 |
| ifrs-full | ImpairmentLossRecognisedInProfitOrLossGoodwill | ImpairmentLossRecognisedInProfitOrLossGoodwill | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill | ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill | USD | 230.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment | ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment | USD | 13.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ImpairmentLossRecognisedInProfitOrLossRightofuseAssets | ImpairmentLossRecognisedInProfitOrLossRightofuseAssets | USD | 7.00M | 2024-01-01 | 2024-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncomeFromSubleasingRightofuseAssets | IncomeFromSubleasingRightofuseAssets | USD | 3.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 |
| ifrs-full | IncomeTaxesPaidRefund | IncomeTaxesPaidRefund | USD | 2.75B | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-02-18 | 0001104659-25-014750 |
| ifrs-full | IncomeTaxesPaidRefundClassifiedAsOperatingActivities | IncomeTaxesPaidRefundClassifiedAsOperatingActivities | USD | 2.85B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncomeTaxExpenseContinuingOperations | IncomeTaxExpenseContinuingOperations | USD | 2.17B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncomeTaxRelatingToAvailableforsaleFinancialAssetsOfOtherComprehensiveIncome | IncomeTaxRelatingToAvailableforsaleFinancialAssetsOfOtherComprehensiveIncome | USD | -2.00M | 2017-01-01 | 2017-12-31 | 2019 | FY | 20-F | 2020-03-03 | 0001104659-20-028557 |
| ifrs-full | IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome | IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome | USD | -16.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome | IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome | USD | 91.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss | IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss | USD | 50.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss | IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss | USD | 94.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome | IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome | USD | -57.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 |
| ifrs-full | IncomeTaxRelatingToHedgesOfNetInvestmentsInForeignOperationsOfOtherComprehensiveIncome | IncomeTaxRelatingToHedgesOfNetInvestmentsInForeignOperationsOfOtherComprehensiveIncome | USD | 66.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome | IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome | USD | 25.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncomeTaxRelatingToOtherIndividuallyImmaterialComponentsOfOtherComprehensiveIncome | IncomeTaxRelatingToOtherIndividuallyImmaterialComponentsOfOtherComprehensiveIncome | USD | -1.00M | 2016-01-01 | 2016-12-31 | 2018 | FY | 20-F | 2019-03-05 | 0001104659-19-012881 |
| ifrs-full | IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome | IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome | USD | 69.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncreaseDecreaseInAccumulatedDeferredTaxRecognisedInOtherComprehensiveIncomeDueToChangeInTaxRate | IncreaseDecreaseInAccumulatedDeferredTaxRecognisedInOtherComprehensiveIncomeDueToChangeInTaxRate | USD | -195.00M | 2021-01-01 | 2021-12-31 | 2023 | FY | 20-F | 2024-02-20 | 0001104659-24-025553 |
| ifrs-full | IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges | IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges | USD | 223.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncreaseDecreaseInDeferredTaxLiabilityAsset | IncreaseDecreaseInDeferredTaxLiabilityAsset | USD | -277.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncreaseDecreaseInExistingProvisionsOtherProvisions | IncreaseDecreaseInExistingProvisionsOtherProvisions | USD | 698.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncreaseDecreaseInNetDefinedBenefitLiabilityAsset | IncreaseDecreaseInNetDefinedBenefitLiabilityAsset | USD | -64.00M | 2020-01-01 | 2020-12-31 | 2020 | FY | 20-F | 2021-02-16 | 0001104659-21-022456 |
| ifrs-full | IncreaseDecreaseInNumberOfSharesOutstanding | IncreaseDecreaseInNumberOfSharesOutstanding | shares | 907,239 | 2019-01-01 | 2019-12-31 | 2020 | FY | 20-F | 2021-02-16 | 0001104659-21-022456 |
| ifrs-full | IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset | IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset | USD | 4.17B | 2021-01-01 | 2021-12-31 | 2023 | FY | 20-F | 2024-02-20 | 0001104659-24-025553 |
| ifrs-full | IncreaseDecreaseThroughChangeInDiscountRateContingentLiabilitiesRecognisedInBusinessCombination | IncreaseDecreaseThroughChangeInDiscountRateContingentLiabilitiesRecognisedInBusinessCombination | USD | -112.00M | 2021-01-01 | 2021-06-30 | 2021 | Q2 | 6-K | 2021-07-30 | 0001104659-21-097781 |
| ifrs-full | IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl | IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl | USD | -257.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities | IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities | USD | 692.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities | IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities | USD | -2.02B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset | IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset | USD | -99.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions | IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions | USD | 122.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities | IncreaseDecreaseThroughObtainingOrLosingControlOfSubsidiariesOrOtherBusinessesLiabilitiesArisingFromFinancingActivities | USD | 12.00M | 2024-01-01 | 2024-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities | IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities | USD | 138.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncreaseDecreaseThroughSharebasedPaymentTransactions | IncreaseDecreaseThroughSharebasedPaymentTransactions | USD | 719.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions | IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions | USD | 258.00M | 2020-01-01 | 2020-12-31 | 2022 | FY | 20-F | 2023-02-21 | 0001104659-23-023818 |
| ifrs-full | IncreaseDecreaseThroughTreasuryShareTransactions | IncreaseDecreaseThroughTreasuryShareTransactions | USD | 43.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncreaseThroughAdjustmentsArisingFromPassageOfTimeContingentLiabilitiesRecognisedInBusinessCombination | IncreaseThroughAdjustmentsArisingFromPassageOfTimeContingentLiabilitiesRecognisedInBusinessCombination | USD | 60.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities | IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities | USD | 566.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | IntangibleAssetsOtherThanGoodwill | IntangibleAssetsOtherThanGoodwill | USD | 37.85B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | InterestCostsCapitalised | InterestCostsCapitalised | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | InterestExpenseDefinedBenefitPlans | InterestExpenseDefinedBenefitPlans | USD | 340.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | InterestExpenseIncomeDefinedBenefitPlans | InterestExpenseIncomeDefinedBenefitPlans | USD | 51.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | InterestExpenseOnBankLoansAndOverdrafts | InterestExpenseOnBankLoansAndOverdrafts | USD | 74.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 |
| ifrs-full | InterestExpenseOnBorrowings | InterestExpenseOnBorrowings | USD | 1.33B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | InterestExpenseOnDebtInstrumentsIssued | InterestExpenseOnDebtInstrumentsIssued | USD | 700.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 |
| ifrs-full | InterestExpenseOnLeaseLiabilities | InterestExpenseOnLeaseLiabilities | USD | 80.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | InterestIncomeDefinedBenefitPlans | InterestIncomeDefinedBenefitPlans | USD | 289.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | InterestIncomeOnDeposits | InterestIncomeOnDeposits | USD | 11.00M | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 |
| ifrs-full | InterestIncomeOnLoansAndReceivables | InterestIncomeOnLoansAndReceivables | USD | 3.00M | 2022-01-01 | 2022-12-31 | 2022 | FY | 20-F | 2023-02-21 | 0001104659-23-023818 |
| ifrs-full | InterestPaidClassifiedAsOperatingActivities | InterestPaidClassifiedAsOperatingActivities | USD | 1.32B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | InterestReceivedClassifiedAsInvestingActivities | InterestReceivedClassifiedAsInvestingActivities | USD | 286.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | Inventories | Inventories | USD | 6.56B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | InventoryWritedown2011 | InventoryWritedown2011 | USD | 664.00M | 2024-01-01 | 2024-12-31 | 2024 | FY | 20-F | 2025-02-18 | 0001104659-25-014750 |
| ifrs-full | InvestmentAccountedForUsingEquityMethod | InvestmentAccountedForUsingEquityMethod | USD | 302.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | InvestmentsInSubsidiariesJointVenturesAndAssociates | InvestmentsInSubsidiariesJointVenturesAndAssociates | USD | 157.00M | 2018-06-30 | 2018 | Q2 | 6-K | 2018-07-26 | 0001104659-18-047274 | |
| ifrs-full | IssuedCapital | IssuedCapital | USD | 388.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | IssueOfEquity | IssueOfEquity | USD | 40.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | KeyManagementPersonnelCompensation | KeyManagementPersonnelCompensation | USD | 99.39M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | KeyManagementPersonnelCompensationPostemploymentBenefits | KeyManagementPersonnelCompensationPostemploymentBenefits | USD | 995,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | KeyManagementPersonnelCompensationSharebasedPayment | KeyManagementPersonnelCompensationSharebasedPayment | USD | 58.91M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | KeyManagementPersonnelCompensationShorttermEmployeeBenefits | KeyManagementPersonnelCompensationShorttermEmployeeBenefits | USD | 39.48M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | LeaseAndSubleasePaymentsRecognisedAsExpense | LeaseAndSubleasePaymentsRecognisedAsExpense | USD | 188.00M | 2018-01-01 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-05 | 0001104659-19-012881 |
| ifrs-full | LeaseLiabilities | LeaseLiabilities | USD | 1.80B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | Liabilities | Liabilities | USD | 65.36B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | LiabilitiesArisingFromFinancingActivities | LiabilitiesArisingFromFinancingActivities | USD | 29.62B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | LongtermBorrowings | LongtermBorrowings | USD | 24.71B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | LossesOnChangeInFairValueOfDerivatives | LossesOnChangeInFairValueOfDerivatives | USD | 49.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | MergerReserve | MergerReserve | USD | 448.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease | MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease | USD | 684.00M | 2018-12-31 | 2018 | FY | 20-F | 2019-03-05 | 0001104659-19-012881 | |
| ifrs-full | MiscellaneousOtherOperatingExpense | MiscellaneousOtherOperatingExpense | USD | 68.00M | 2020-01-01 | 2020-12-31 | 2020 | FY | 20-F | 2021-02-16 | 0001104659-21-022456 |
| ifrs-full | MiscellaneousOtherOperatingIncome | MiscellaneousOtherOperatingIncome | USD | 406.00M | 2020-01-01 | 2020-12-31 | 2020 | FY | 20-F | 2021-02-16 | 0001104659-21-022456 |
| ifrs-full | NetAssetsLiabilities | NetAssetsLiabilities | USD | 48.72B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NetDebt | NetDebt | USD | 23.37B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NetDeferredTaxAssets | NetDeferredTaxAssets | USD | 8.00B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NetDeferredTaxLiabilities | NetDeferredTaxLiabilities | USD | 5.68B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements | NetFinancialAssetsSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements | USD | 82.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements | NetFinancialLiabilitiesSubjectToOffsettingEnforceableMasterNettingArrangementsOrSimilarAgreements | USD | 26.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NetForeignExchangeGain | NetForeignExchangeGain | USD | 8.00M | 2016-01-01 | 2016-12-31 | 2018 | FY | 20-F | 2019-03-05 | 0001104659-19-012881 |
| ifrs-full | NetForeignExchangeLoss | NetForeignExchangeLoss | USD | 31.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination | NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination | USD | 198.00M | 2024-01-01 | 2024-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | NoncontrollingInterests | NoncontrollingInterests | USD | 52.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NoncurrentAccruedIncome | NoncurrentAccruedIncome | USD | 56.00M | 2020-12-31 | 2020 | FY | 20-F | 2021-02-16 | 0001104659-21-022456 | |
| ifrs-full | NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets | NoncurrentAccruedIncomeOtherThanNoncurrentContractAssets | USD | 75.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NoncurrentAssets | NoncurrentAssets | USD | 85.35B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners | NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners | USD | 0 | 2024-12-31 | 2024 | FY | 20-F | 2025-02-18 | 0001104659-25-014750 | |
| ifrs-full | NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts | NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts | USD | 74.42B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NoncurrentContractLiabilities | NoncurrentContractLiabilities | USD | 7.00M | 2023-12-31 | 2024 | FY | 20-F | 2025-02-18 | 0001104659-25-014750 | |
| ifrs-full | NoncurrentDerivativeFinancialAssets | NoncurrentDerivativeFinancialAssets | USD | 498.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NoncurrentDerivativeFinancialLiabilities | NoncurrentDerivativeFinancialLiabilities | USD | 115.00M | 2024-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NoncurrentFinancialAssets | NoncurrentFinancialAssets | USD | 1.17B | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 | |
| ifrs-full | NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome | NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome | USD | 1.17B | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 | |
| ifrs-full | NoncurrentFinancialAssetsAvailableforsale | NoncurrentFinancialAssetsAvailableforsale | USD | 933.00M | 2017-12-31 | 2019 | FY | 20-F | 2020-03-03 | 0001104659-20-028557 | |
| ifrs-full | NoncurrentGovernmentGrants | NoncurrentGovernmentGrants | USD | 55.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | USD | 2.22B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NoncurrentLeaseLiabilities | NoncurrentLeaseLiabilities | USD | 1.42B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NoncurrentLiabilities | NoncurrentLiabilities | USD | 34.74B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NoncurrentPayables | NoncurrentPayables | USD | 2.38B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NoncurrentPortionOfNoncurrentSecuredBankLoansReceived | NoncurrentPortionOfNoncurrentSecuredBankLoansReceived | USD | 0 | 2023-12-31 | 2024 | FY | 20-F | 2025-02-18 | 0001104659-25-014750 | |
| ifrs-full | NoncurrentPrepayments | NoncurrentPrepayments | USD | 559.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NoncurrentProvisions | NoncurrentProvisions | USD | 918.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NoncurrentRecognisedAssetsDefinedBenefitPlan | NoncurrentRecognisedAssetsDefinedBenefitPlan | USD | 106.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NoncurrentRecognisedLiabilitiesDefinedBenefitPlan | NoncurrentRecognisedLiabilitiesDefinedBenefitPlan | USD | 1.10B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NumberOfEmployees | NumberOfEmployees | employee | 96,100 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | NumberOfInstrumentsOtherEquityInstrumentsGranted | NumberOfInstrumentsOtherEquityInstrumentsGranted | shares | 267,000 | 2023-01-01 | 2023-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | OtherAdjustmentsForNoncashItems | OtherAdjustmentsForNoncashItems | USD | 662.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | OtherAssetsAmountContributedToFairValueOfPlanAssets | OtherAssetsAmountContributedToFairValueOfPlanAssets | USD | 251.00M | 2018-12-31 | 2018 | FY | 20-F | 2019-03-05 | 0001104659-19-012881 | |
| ifrs-full | OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities | OtherCashPaymentsToAcquireEquityOrDebtInstrumentsOfOtherEntitiesClassifiedAsInvestingActivities | USD | 5.00M | 2022-01-01 | 2022-06-30 | 2022 | Q2 | 6-K | 2022-07-29 | 0001104659-22-083922 |
| ifrs-full | OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities | OtherCashPaymentsToAcquireInterestsInJointVenturesClassifiedAsInvestingActivities | USD | 10.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities | OtherCashReceiptsFromSalesOfInterestsInJointVenturesClassifiedAsInvestingActivities | USD | 776.00M | 2021-01-01 | 2021-06-30 | 2021 | Q2 | 6-K/A | 2021-07-30 | 0001104659-21-097940 |
| ifrs-full | OtherComprehensiveIncome | OtherComprehensiveIncome | USD | 2.70B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | OtherComprehensiveIncomeBeforeTaxAvailableforsaleFinancialAssets | OtherComprehensiveIncomeBeforeTaxAvailableforsaleFinancialAssets | USD | -83.00M | 2017-01-01 | 2017-12-31 | 2019 | FY | 20-F | 2020-03-03 | 0001104659-20-028557 |
| ifrs-full | OtherComprehensiveIncomeBeforeTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability | OtherComprehensiveIncomeBeforeTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability | USD | 12.00M | 2024-01-01 | 2024-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation | OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation | USD | 2.39B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | OtherComprehensiveIncomeBeforeTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome | OtherComprehensiveIncomeBeforeTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome | USD | 0 | 2018-01-01 | 2018-06-30 | 2018 | Q2 | 6-K | 2018-07-26 | 0001104659-18-047274 |
| ifrs-full | OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments | OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments | USD | 188.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans | OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans | USD | 290.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | OtherComprehensiveIncomeBeforeTaxHedgesOfNetInvestmentsInForeignOperations | OtherComprehensiveIncomeBeforeTaxHedgesOfNetInvestmentsInForeignOperations | USD | 14.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets | OtherComprehensiveIncomeNetOfTaxAvailableforsaleFinancialAssets | USD | 0 | 2018-01-01 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-05 | 0001104659-19-012881 |
| ifrs-full | OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax | OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax | USD | 2.32B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax | OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax | USD | 384.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | OtherCurrentPayables | OtherCurrentPayables | USD | 1.67B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | OtherCurrentReceivables | OtherCurrentReceivables | USD | 2.02B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | OtherEmployeeExpense | OtherEmployeeExpense | USD | 1.61B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities | OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities | USD | 161.00M | 2023-01-01 | 2023-12-31 | 2023 | FY | 20-F | 2024-02-20 | 0001104659-24-025553 |
| ifrs-full | OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities | OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities | USD | 131.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | OtherNoncurrentPayables | OtherNoncurrentPayables | USD | 2.04B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | OtherNoncurrentReceivables | OtherNoncurrentReceivables | USD | 1.33B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | OtherOperatingIncomeExpense | OtherOperatingIncomeExpense | USD | 381.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | OtherProvisions | OtherProvisions | USD | 1.72B | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 | |
| ifrs-full | OtherReserves | OtherReserves | USD | 2.07B | 2025-06-30 | 2025 | Q2 | 6-K | 2025-07-29 | 0001104659-25-071432 | |
| ifrs-full | OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome | OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome | USD | -360.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ParValuePerShare | ParValuePerShare | USD/shares | 0.25 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | PastServiceCostDefinedBenefitPlans | PastServiceCostDefinedBenefitPlans | USD | -26.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | PaymentsFromChangesInOwnershipInterestsInSubsidiaries | PaymentsFromChangesInOwnershipInterestsInSubsidiaries | USD | 183.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities | PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities | USD | 14.00M | 2017-01-01 | 2017-12-31 | 2018 | FY | 20-F | 2019-03-05 | 0001104659-19-012881 |
| ifrs-full | PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities | PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities | USD | 372.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | PaymentsToAcquireOrRedeemEntitysShares | PaymentsToAcquireOrRedeemEntitysShares | USD | 521.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | PercentageOfReasonablyPossibleDecreaseInActuarialAssumption | PercentageOfReasonablyPossibleDecreaseInActuarialAssumption | pure | 0.005 | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 | |
| ifrs-full | PercentageOfReasonablyPossibleIncreaseInActuarialAssumption | PercentageOfReasonablyPossibleIncreaseInActuarialAssumption | pure | 0.005 | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 | |
| ifrs-full | PlanAssetsAtFairValue | PlanAssetsAtFairValue | USD | 6.48B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | PostemploymentBenefitExpenseDefinedBenefitPlans | PostemploymentBenefitExpenseDefinedBenefitPlans | USD | 116.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | PostemploymentBenefitExpenseDefinedContributionPlans | PostemploymentBenefitExpenseDefinedContributionPlans | USD | 553.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | PostemploymentBenefitExpenseInProfitOrLoss | PostemploymentBenefitExpenseInProfitOrLoss | USD | 618.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ProceedsFromBorrowingsClassifiedAsFinancingActivities | ProceedsFromBorrowingsClassifiedAsFinancingActivities | USD | 15.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ProceedsFromIssuingShares | ProceedsFromIssuingShares | USD | 40.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities | ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities | USD | 78.00M | 2024-01-01 | 2024-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities | ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities | USD | 136.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod | ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod | USD | 13.00M | 2024-01-01 | 2024-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities | ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities | USD | 13.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ProfitLoss | ProfitLoss | USD | 10.23B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ProfitLossAttributableToNoncontrollingInterests | ProfitLossAttributableToNoncontrollingInterests | USD | 8.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity | ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity | USD | 10.22B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ProfitLossAttributableToOwnersOfParent | ProfitLossAttributableToOwnersOfParent | USD | 10.22B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ProfitLossBeforeTax | ProfitLossBeforeTax | USD | 12.40B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ProfitLossFromOperatingActivities | ProfitLossFromOperatingActivities | USD | 13.74B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | PropertyPlantAndEquipment | PropertyPlantAndEquipment | USD | 12.96B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | ProportionOfVotingPowerHeldInAssociate | ProportionOfVotingPowerHeldInAssociate | pure | 0.29 | 2019-10-08 | 2019 | FY | 20-F | 2020-03-03 | 0001104659-20-028557 | |
| ifrs-full | Provisions | Provisions | USD | 1.60B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | ProvisionUsedOtherProvisions | ProvisionUsedOtherProvisions | USD | 1.25B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities | PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities | USD | 3.10B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod | PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod | USD | 140.00M | 2024-01-01 | 2024-06-30 | 2025 | Q2 | 6-K | 2025-07-29 | 0001104659-25-071432 |
| ifrs-full | PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities | PurchaseOfOtherLongtermAssetsClassifiedAsInvestingActivities | USD | 229.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities | PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities | USD | 2.81B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | PurchaseOfTreasuryShares | PurchaseOfTreasuryShares | USD | 0 | 2013-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ReclassificationAdjustmentsOnAvailableforsaleFinancialAssetsNetOfTax | ReclassificationAdjustmentsOnAvailableforsaleFinancialAssetsNetOfTax | USD | -4.00M | 2017-01-01 | 2017-12-31 | 2017 | FY | 20-F | 2018-03-06 | 0001104659-18-015257 |
| ifrs-full | ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax | ReclassificationAdjustmentsOnCashFlowHedgesBeforeTax | USD | 314.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | RecognisedAssetsDefinedBenefitPlan | RecognisedAssetsDefinedBenefitPlan | USD | 99.00M | 2024-12-31 | 2024 | FY | 20-F | 2025-02-18 | 0001104659-25-014750 | |
| ifrs-full | RecognisedLiabilitiesDefinedBenefitPlan | RecognisedLiabilitiesDefinedBenefitPlan | USD | 1.33B | 2024-12-31 | 2024 | FY | 20-F | 2025-02-18 | 0001104659-25-014750 | |
| ifrs-full | RepaymentsOfBondsNotesAndDebentures | RepaymentsOfBondsNotesAndDebentures | USD | 2.57B | 2024-04-01 | 2024-06-30 | 2024 | Q2 | 6-K | 2024-07-25 | 0001104659-24-082531 |
| ifrs-full | RepaymentsOfBorrowingsClassifiedAsFinancingActivities | RepaymentsOfBorrowingsClassifiedAsFinancingActivities | USD | 2.03B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ResearchAndDevelopmentExpense | ResearchAndDevelopmentExpense | USD | 14.23B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ReserveOfExchangeDifferencesOnTranslation | ReserveOfExchangeDifferencesOnTranslation | USD | 0 | 2003-01-01 | 2022 | FY | 20-F | 2023-02-21 | 0001104659-23-023818 | |
| ifrs-full | ReserveOfExchangeDifferencesOnTranslationHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied | ReserveOfExchangeDifferencesOnTranslationHedgingRelationshipsForWhichHedgeAccountingIsNoLongerApplied | USD | 527.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | RestrictedCashAndCashEquivalents | RestrictedCashAndCashEquivalents | USD | 236.00M | 2022-06-30 | 2022 | Q2 | 6-K | 2022-07-29 | 0001104659-22-083922 | |
| ifrs-full | RetainedEarnings | RetainedEarnings | USD | 10.97B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseBeforeTaxDefinedBenefitPlans | ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseBeforeTaxDefinedBenefitPlans | USD | 85.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset | ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset | USD | 932.00M | 2019-01-01 | 2019-12-31 | 2020 | FY | 20-F | 2021-02-16 | 0001104659-21-022456 |
| ifrs-full | Revenue | Revenue | USD | 58.74B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | RevenueFromContractsWithCustomers | RevenueFromContractsWithCustomers | USD | 36.54B | 2021-01-01 | 2021-12-31 | 2021 | FY | 20-F | 2022-02-22 | 0001104659-22-025720 |
| ifrs-full | RevenueFromGovernmentGrants | RevenueFromGovernmentGrants | USD | 222.00M | 2020-01-01 | 2020-12-31 | 2020 | FY | 20-F | 2021-02-16 | 0001104659-21-022456 |
| ifrs-full | RevenueFromSaleOfGoods | RevenueFromSaleOfGoods | USD | 55.57B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod | RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod | USD | 107.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ReversalOfImpairmentLoss | ReversalOfImpairmentLoss | USD | 28.00M | 2018-01-01 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-05 | 0001104659-19-012881 |
| ifrs-full | ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill | ReversalOfImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ReversedUnsettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination | ReversedUnsettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination | USD | 121.00M | 2022-01-01 | 2022-12-31 | 2024 | FY | 20-F | 2025-02-18 | 0001104659-25-014750 |
| ifrs-full | ReverseRepurchaseAgreementsAndCashCollateralOnSecuritiesBorrowed | ReverseRepurchaseAgreementsAndCashCollateralOnSecuritiesBorrowed | USD | 22.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | RightofuseAssets | RightofuseAssets | USD | 1.74B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | RoyaltyExpense | RoyaltyExpense | USD | 4.00M | 2018-01-01 | 2018-12-31 | 2018 | FY | 20-F | 2019-03-05 | 0001104659-19-012881 |
| ifrs-full | SellingGeneralAndAdministrativeExpense | SellingGeneralAndAdministrativeExpense | USD | 19.93B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination | SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination | USD | 1.16B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod | ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod | USD | -7.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | SharePremium | SharePremium | USD | 35.27B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates | SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates | shares | 147,547 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | ShorttermDepositsClassifiedAsCashEquivalents | ShorttermDepositsClassifiedAsCashEquivalents | USD | 4.38B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | ShorttermDepositsNotClassifiedAsCashEquivalents | ShorttermDepositsNotClassifiedAsCashEquivalents | USD | 64.00M | 2022-12-31 | 2024 | FY | 20-F | 2025-02-18 | 0001104659-25-014750 | |
| ifrs-full | ShorttermInvestmentsClassifiedAsCashEquivalents | ShorttermInvestmentsClassifiedAsCashEquivalents | USD | 1.15B | 2017-12-31 | 2017 | FY | 20-F | 2018-03-06 | 0001104659-18-015257 | |
| ifrs-full | SocialSecurityContributions | SocialSecurityContributions | USD | 1.35B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | SurplusDeficitInPlan | SurplusDeficitInPlan | USD | -999.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense | TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense | USD | 105.00M | 2017-01-01 | 2017-12-31 | 2018 | FY | 20-F | 2019-03-05 | 0001104659-19-012881 |
| ifrs-full | TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense | TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense | USD | 22.00M | 2020-01-01 | 2020-12-31 | 2022 | FY | 20-F | 2023-02-21 | 0001104659-23-023818 |
| ifrs-full | TaxEffectFromChangeInTaxRate | TaxEffectFromChangeInTaxRate | USD | -23.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss | TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss | USD | 101.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | TaxEffectOfForeignTaxRates | TaxEffectOfForeignTaxRates | USD | -168.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | TaxEffectOfRevenuesExemptFromTaxation2011 | TaxEffectOfRevenuesExemptFromTaxation2011 | USD | 163.00M | 2021-01-01 | 2021-12-31 | 2023 | FY | 20-F | 2024-02-20 | 0001104659-24-025553 |
| ifrs-full | TaxEffectOfTaxLosses | TaxEffectOfTaxLosses | USD | 86.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | TaxExpenseIncomeAtApplicableTaxRate | TaxExpenseIncomeAtApplicableTaxRate | USD | 3.10B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures | TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures | USD | 8.46B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | TerminationBenefitsExpense | TerminationBenefitsExpense | USD | 190.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | TradeAndOtherCurrentPayables | TradeAndOtherCurrentPayables | USD | 25.28B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | TradeAndOtherCurrentPayablesToTradeSuppliers | TradeAndOtherCurrentPayablesToTradeSuppliers | USD | 3.82B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | TradeAndOtherCurrentReceivables | TradeAndOtherCurrentReceivables | USD | 15.18B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | TradingIncomeExpenseOnForeignExchangeContracts | TradingIncomeExpenseOnForeignExchangeContracts | USD | 190.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | TreasuryShares | TreasuryShares | USD | 25.00M | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | UndrawnBorrowingFacilities | UndrawnBorrowingFacilities | USD | 4.88B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | UnusedProvisionReversedOtherProvisions | UnusedProvisionReversedOtherProvisions | USD | 157.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | WagesAndSalaries | WagesAndSalaries | USD | 10.97B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | WeightedAverageShares | WeightedAverageShares | shares | 1.55B | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | WorkInProgress | WorkInProgress | USD | 2.78B | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 | |
| ifrs-full | WritedownsReversalsOfInventories | WritedownsReversalsOfInventories | USD | 314.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 20-F | 2026-02-24 | 0001104659-26-019130 |
| ifrs-full | WritedownsReversalsOfPropertyPlantAndEquipment | WritedownsReversalsOfPropertyPlantAndEquipment | USD | 343.00M | 2021-01-01 | 2021-12-31 | 2023 | FY | 20-F | 2024-02-20 | 0001104659-24-025553 |